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Abstract 
 
Facial skin cancer secondary to surgical treatment may be distressing due to the 
malignancy itself and from the consequences of its treatment.  A visible postsurgical scar 
is an obvious reminder of the condition.  This investigation sought to broaden our 
understanding of facial scarring and develop a novel tool for its objective evaluation. To 
this end, skin cancer as the most common etiology of facial scarring was reviewed. The 
scar scale literature was evaluated in the context of assessing scars through a 
biopsychosocial lens.  Finally, the development of a novel scar scale was presented.  
Thirty-four individuals completed 13,056 ratings using a novel scar scale – the Scar 
Camouflage Scale (SCS).  Preliminary data demonstrated intra-rater agreement of 0.74 - 
0.92 and between-rater agreement of 0.78 - 0.96.  In conclusion, through rigorous 
methodology this investigation provides preliminary support for the establishment and 
use of the Scar Camouflage Scale (SCS). These results provide the empiric basis for 
wholistic scar evaluation. 
Keywords: Skin Cancer, Non-melanoma, Facial Scar, Scar Scale, Scar Evaluation 
 
  
   
 
 ii 
Summary for a Lay Audience 
Facial skin cancer is an anxiety provoking condition. Not only is the diagnosis 
distressing, but so too is the consequence of its treatment which is most commonly 
surgery.  Regardless of location, every surgery will result in some form of scarring.  
When this affects the face, scarring is a visible daily reminder of the condition, one that 
may also impact one’s physical appearance and body image.   
Many factors contribute to how a scar impacts an individual’s body image.  Few 
research studies have been able to holistically understand these factors, or determine how 
the scar itself contributes to the person’s overall body image and self-perception.  One of 
the main difficulties lies in the way scars are currently evaluated.  The research conducted 
has been somewhat inconsistent and we remain without a standardized way to measure 
scars.  
This investigation sought to improve our understanding of facial scarring and 
develop a new scar measurement tool.  To achieve these goals, we reviewed the most 
common reason that an individual might acquire a facial scar – facial skin cancer.  We 
then assessed how scars affect a person relative to their psychological and social impact.  
To this end, we reviewed all relevant literature and aimed to place these in the context of 
what is termed the “biopsychosocial” model of health.  Finally, we presented the results 
of a study that sought to develop a new scar scale called the Scar Camouflage Scale 
(SCS). 
The results of this study demonstrate that individuals can reliably measure scars 
using the SCS, even when different individuals measure the same scar.  These data 
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provide the necessary evidence to support further research using the SCS and apply this 
research to help understand the comprehensive impact of facial scarring.   
 
   
 
 iv 
Co-Authorship Statement 
 
 
Co-Authorship  
 
I hereby declare that this thesis incorporates material that is result of joint research, as 
follows:  Chapter 2 of the thesis was co-authored with Dr. Corey Moore.  In all cases, the key 
ideas, primary contributions, and writing were performed by the author, and the contribution of 
Dr. Corey Moore was primarily through the provision of clinical photographs, feedback of ideas, 
and editing of the manuscript.   
I certify that, with the above qualification, this thesis, and the research to which it refers, is 
the product of my own work. 
 
Previous Publication 
 
This thesis includes one original paper that has been previously published/submitted 
for publication in peer reviewed journals, as follows: 
 
Thesis Chapter Publication title/full citation Publication status 
Chapter 2 Brandt, M. G., Moore, C. C. (2019). 
Nonmelanoma Skin Cancer.  Facial 
plastic surgery clinics of North 
America, 27(1), 1-13. 
Published 
 
I certify that I have retained permission from the copyright owner(s) to include the 
above published material(s) in my thesis. I certify that the above material describes work 
completed during my registration as a graduate student at Western University 
 
  
   
 
 v 
Acknowledgements 
I wish to express my sincere appreciation to my friend and supervisor, Dr. Philip 
Doyle, who has guided and encouraged me through this and many other projects.  His 
kindness, integrity, and passion have been a source of inspiration and academic curiosity.  
I can confidently attest that without his persistence and compassion, this project would 
not have been realized.  
I am especially indebted to Dr. Corey Moore. As my teacher and mentor, he has 
taught me more than I could ever give him credit for here.  From the day we first met, he 
has motivated my clinical passions and inspired creativity and innovative problem 
solving.  I wish to thank him for his friendship, guidance, and incredible sense of humor. 
I wish to thank my patients for their photos, feedback, and the humbling 
opportunity to share in their most intimate challenges.  I continue to learn and grow from 
each individual patient encounter.  Their courage and resiliency in the face of adversity 
compels me to be a better physician and surgeon.     
This project would not have been possible without the willingness of so many 
gracious participants. I am forever grateful for their altruism.  
I would like to thank my parents, who have always supported and motivated me. 
Much of my passion for research stems from my late father who always encouraged 
analysis and critical appraisal and once commented that he always wished he could “do 
scientific research”.   
Finally, and most importantly, I wish to thank my loving and supportive wife, 
Naomi, and my three wonderful children, Eden, Levi and Yael, who provide unending 
   
 
 vi 
support and inspiration.  Nobody has taught me more about love, compassion, humility, 
and the true meaning of life.  
  
   
 
 vii 
Table of Contents 
 
Abstract ...................................................................................................................... i 
Summary for a Lay Audience .................................................................................... ii 
Co-Authorship Statement .......................................................................................... iv 
Acknowledgements ................................................................................................... v 
List of Tables ............................................................................................................. xi 
List of Figures ............................................................................................................ xii 
Chapter 1: Introduction and Background .................................................................. 1 
Introduction ................................................................................................... 1 
Impact of Facial Skin Scarring ...................................................................... 1 
Objective Scar Scaling ................................................................................... 3 
Statement of Problem .................................................................................... 5 
Chapter 2: Contemporary Management of Non-Melanoma Skin Cancer ................. 6 
Keratinocyte Carcinomas .............................................................................. 6 
Aetiology ........................................................................................... 7 
Clinical Features and Work Up ......................................................... 9 
Basal Cell Carcinoma ........................................................................ 10 
Squamous Cell Carcinoma ................................................................ 12 
Management ...................................................................................... 13 
Biopsy .................................................................................... 13 
Resection of the Primary Malignancy ................................... 13 
Incomplete Excisions and Aggressive Features on 
Pathology ............................................................................... 
 
14 
   
 
 viii 
Advanced Disease .................................................................. 15 
Less Common Non-Melanoma Skin Cancers ............................................... 16 
Merkel Cell Carcinoma ..................................................................... 16 
Clinical Features and Work-up .............................................. 16 
Management .......................................................................... 17 
Adnexal Carcinomas of the Skin ....................................................... 19 
Sarcomas of the Skin ......................................................................... 23 
Dermatofibrosarcoma protuberans (DFSP) ........................... 24 
Clinical Features and Work-up .................................. 24 
Management .............................................................. 25 
Atypical Fibroxanthoma ........................................................ 25 
Clinical Features and Work-up .................................. 26 
Management .............................................................. 26 
Angiosarcomas ...................................................................... 27 
Clinical Features and Work-up .................................. 27 
Management .............................................................. 28 
Summary ........................................................................................................ 28 
Chapter 3: ICF and Skin Scarring .............................................................................. 29 
Skin Scarring through the ICF model ............................................................ 29 
Contemporary Objective Scar Evaluation ..................................................... 31 
Visual Analog Scaling ................................................................................... 32 
The Patient’s Perspective ............................................................................... 33 
Social Impairment .......................................................................................... 33 
   
 
 ix 
Summary: The Need for a Biopsychosocial Lens ......................................... 34 
Chapter 4: Preliminary Reliability Analysis of a Novel Scale for the Objective 
Evaluation of Linear Scars ........................................................................................ 
 
36 
Introduction ................................................................................................... 36 
Literature Review and Critical Appraisal .......................................... 36 
Objective ............................................................................................ 38 
Methods ......................................................................................................... 38 
Participants ........................................................................................ 38 
Sample size calculation ..................................................................... 39 
Design ................................................................................................ 39 
Phase 1: Scale Development .................................................. 39 
Phase 2: Scar Evaluation Automation ................................... 45 
Phase 3: Scar Evaluation ....................................................... 46 
Procedure ........................................................................................... 47 
Outcome Measures and Statistical Analysis ...................................... 48 
Results ........................................................................................................... 49 
Discussion ...................................................................................................... 53 
Conclusions ................................................................................................... 57 
Chapter 5: Conclusions and Bringing it all Together ................................................ 58 
Skin Cancer .................................................................................................... 58 
Facial Scarring ............................................................................................... 59 
Scar Scaling ................................................................................................... 59 
Clinical Implications ...................................................................................... 61 
   
 
 x 
Directions for Future Research ...................................................................... 62 
Limitations of the Present Project ................................................................. 64 
Summary ........................................................................................................ 65 
References ................................................................................................................. 67 
Appendix A: Health Sciences Research Ethics Board Approval............................... 81 
Curriculum Vitae ....................................................................................................... 82 
 
 
   
 
 xi 
List of Tables 
 Page 
Table 2.1: Risk factors for the development of Keratinocyte Carcinomas ............... 8 
Table 2.2: Common Clinical Features of Keratinocyte Carcinomas ......................... 9 
Table 2.3: Eccrine and Apocrine Gland Carcinomas ................................................ 20 
Table 2.4: Carcinomas of the Hair Follicle ............................................................... 22 
Table 2.5: Carcinomas of the Sebaceous Glands ...................................................... 23 
Table 4.1: Scar Scale Dimensions ............................................................................. 42 
Table 4.2: Scar Photo Range of Responses ............................................................... 51 
Table 4.3: Within-rater agreement for the eight scaled dimensions .......................... 51 
Table 4.4: Between-rater agreement for the eight scaled dimensions ....................... 52 
Table 4.5: Comparison of Scar Camouflage Scale to other Scar Rating Scales ....... 55 
Table 5.1: Scar Evaluation Dimensions .................................................................... 60 
 
   
 
 xii 
List of Figures 
 Page 
Figure 1: Obvious Upper Lip / Cheek Scar ............................................................... 4 
Figure 1.2: Well-Camouflaged Left Upper Eyelid Scar ............................................ 4 
Figure 2.1: Nodular BCCs ......................................................................................... 10 
Figure 2.2: Superficial BCCs ..................................................................................... 11 
Figure 2.3: Sclerosing BCCs ..................................................................................... 11 
Figure 2.4: Cutaneous SCCs ...................................................................................... 12 
Figure 2.5: Merkel Cell Carcinomas ......................................................................... 17 
Figure 4.1: ScARS – Scar Rating Software ............................................................... 46 
Figure 4.2: Mean Scar Photo Ratings ........................................................................ 50 
 
   
 
 1 
Chapter 1: Introduction and Background 
Introduction 
Non-melanoma skin cancer is the most common form of cancer with an estimated 
annual incidence of 80,000 cases in Canada per year (Canadian Cancer Society, 2014). 
The head and neck regions are the most common areas of the body affected (Norval et al., 
2014).  Given the visibility of a skin cancer lesion on the face, it is not surprising that 
these lesions result in some form of facial disfigurement.  A team of investigators at 
Johns Hopkins University (Baltimore, Maryland, USA) characterized this facial 
disfigurement an “attractiveness penalty” – largely influenced by the size, depth and 
location of the facial lesion (Cassileth et al., 1983; Godoy et al., 2011).   In addition to the 
“attractiveness penalty”, individuals with facial lesions have perceived negative affect 
resulting in an overall “social penalty” that decreases observer comfort when conversing 
with these individuals socially (Dey, Ishii, Byrne, et al., 2015).  Accordingly, removal of 
the skin cancer and subsequent repair of the removal defect is critical to normalizing 
these individuals’ appearance and restoring their sense of well-being and social 
functioning (Godoy et al., 2011).   
Impact of Facial Skin Scarring  
Like all surgery, removal of a skin cancer and repair of the subsequent defect 
results in some degree of surgical scarring. A paper published by Sobanko and colleagues 
(2015) reviews the impact of skin cancer vis-à-vis an individual’s appearance (Sobanko 
et al., 2015).  To summarize, individuals with a facial scar are stigmatized and more 
likely to be judged as dysfunctional, dishonest, unsuitable for employment, unintelligent, 
and unattractive (Borah & Rankin, 2010; Ishii et al., 2009; Kim et al., 2013; Rankin & 
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Borah, 2003; Sobanko et al., 2015).  Perceived stigma by those with a facial lesion or scar 
can result in an impairment of communication, and restrictions of personal relationships 
in addition to social and vocational activities (Brown et al., 2010; Sobanko et al., 2015).  
Importantly, it is the individuals’ own subjective perception of their scar visibility and not 
their observed degree of scarring that directly impairs their psychosocial functioning 
(Brown et al., 2010; Sobanko et al., 2015).  Thus, skin cancer surgery often results in 
appearance-related anxiety resulting in impairments of quality of life and financial 
stability – with many going on employment disability due to the psychosocial burden of 
disfigurement (Sobanko et al., 2015).  Finally, facial disfigurement in the form of a scar is 
so distressing that >50% of adults would risk a 7% chance of death, and more than 13% 
of adults would accept a 30-45% risk of death, to obtain a “normal” face (Borah & 
Rankin, 2010; Sobanko et al., 2015).  
 The burden of facial skin cancer is substantial.  Facial skin cancer not only 
imparts an “attractiveness penalty” in and of itself, but the resultant scar from its removal 
may also perpetuate psychosocial impairment due to a perceived facial disfigurement.   It 
is not surprising that a well-executed reconstruction following the removal of a facial skin 
cancer can substantially improve an individual’s overall quality of life (Dey, Ishii, 
Boahene, et al., 2015).  But what constitutes a “well-executed reconstruction”?  This 
largely boils down to achieving a “good scar”.  The difficulty herein is that a “good scar” 
is similar to the perception of “talent”; you know a “good scar” when you see it – or 
rather when you do not see it.  Furthermore, it is impossible to ignore the personal factors 
and context of the individual affected by the scar.  A young facial model may be severely 
traumatized by a small objectively minimal facial scar whereas an older individual with 
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substantial facial hair may be relatively unfazed by even a large objectively obvious 
facial scar.   It is the delicate balance of objective scar features, personal factors, and the 
overall context of the individual affected that truly determine the impact of a facial scar 
and its burden to the individual.    To add to this complexity, a paucity of consistency 
exists in the objective scar evaluation literature (Durani et al., 2009).    
Objective Scar Scaling 
When reviewing the scar scaling literature (Durani et al., 2009), a point of 
disparity relates to which scar features should be evaluated and how they each contribute 
to the camouflage of the scar and its overall impact on an individual’s facial appearance.  
In fact, without a clear understanding of which scar dimensions need to be evaluated and 
the mechanism to evaluate them, the logical progression of determining the association of 
each scar dimension on overall scar camouflage or acceptability cannot be done.   What 
has been evaluated thus far are variations on scar dimensions which include how wide or 
stretched a scar appears, its height relative to the surrounding skin, its discolouration 
relative to the surrounding skin, any irregularities in its appearance or distortion of 
surrounding structures, and any evidence of surgery – i.e., suture marks.  Figures 1.1 and 
1.2 illustrate examples of poorly camouflaged and well-camouflaged scars, respectively.   
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     Figure 1.1:  Obvious Upper Lip/Cheek Scar   
 
 
 
 
 
 
Note. A poorly camouflaged scar of the right cheek and upper lip many years 
following a traumatic facial injury. 
      
Figure 1.2:  Well-Camouflaged Left Upper Eyelid Scar: (a) prior to and (b) 3-months 
following surgical excision  
 
  
Note. Purple markings indicate incision lines for removal and reconstruction.   
 
The previously described scar dimensions have been defined in various forms in 
the aforementioned efforts of generating an empirically validated objective scar 
evaluation scale.  The resultant scales from this body of research have included the 
Vancouver Scar Scale, Patient and Observer Scar Scale, Manchester Scar Scale, Stony 
Brook Scar Evaluation Scale, and SCAR scale (Durani et al., 2009; Idriss & Maibach, 
a. b. 
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2009; Perry et al., 2010; Roques & Téot, 2007; Vercelli et al., 2003).  While each of these 
scales demonstrates empiric reliability, they vary in the dimensions being scaled and the 
methods used to scale these dimensions (Brandt et al., 2009; Perry et al., 2010).  Thus, we 
remain without a reliable tool to objectively characterize observed scar outcomes.   
Statement of Problem 
Without a reliable, consistent, and empirically sound means of objectively 
evaluating scars it is impossible to pursue research that relates objective scar outcomes 
with the personal experience of a scar.  Furthermore, and more practically speaking, it is 
similarly impossible to provide empiric recommendations on how to optimize 
postsurgical scarring.   
To provide context, this thesis will begin by exploring the contemporary 
management of skin cancer, as this is the most common means by which an individual 
might obtain a facial scar.  To integrate and understand the impact of facial scarring on an 
individual’s overall wellbeing, facial scarring will be reviewed through the lens of the 
World Health Organization’s International Classification of Functioning, Disability, and 
Health (ICF) (Stephens, 2001).   We will then describe the preliminary validation of a 
novel scar assessment instrument.   Finally, we will strive to integrate the preceding 
discussions and define potential objectives for future investigation.    
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Chapter 2: Contemporary Management of Non-Melanoma Skin Cancer 
“Non-melanoma skin cancer” represents a broad group of cutaneous 
malignancies.  Included in this category are common Keratinocyte Carcinomas (KC) and 
rare neoplasms such as Merkel Cell Carcinoma, Adnexal Carcinomas, and Cutaneous 
Sarcomas.   Although divergent in cell lineage and presentation, these malignancies 
primarily occur in the head and neck region and undoubtedly result in some degree of 
facial disfigurement and morbidity.   Facial plastic surgeons have the unique opportunity 
to both cure a patient of a potentially life threatening malignancy and also improve their 
overall quality of life through a well-executed post-ablative reconstruction (Dey, Ishii, 
Boahene, et al., 2015).  This chapter endeavours to provide the reader with a 
contemporary overview of cutaneous neoplasms that present in the head and neck region.   
Keratinocyte Carcinomas 
Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) represent the 
two most common skin malignancies and are frequently lumped together under the 
umbrella term “Non-Melanoma Skin Cancer”.  These two cutaneous malignancies share a 
cellular lineage with keratinocytes and are thus more accurately termed Keratinocyte 
Carcinomas (Albert & Weinstock, 2003). As a category, Keratinocyte Carcinomas are the 
most common malignancies worldwide – with an annual incidence that exceeds all other 
malignancies combined (Rogers et al., 2015). The incidence of KC continues to grow 
with well-over 3-million treatments for KC in the United States each year (Rogers et al., 
2015). While Keratinocyte Carcinomas are typically well managed and only rarely do 
they metastasize, these lesions can result in substantial morbidity.   
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Aetiology  
While the risk of developing KC is dependent on genotypic, phenotypic, and 
environmental factors, it is well-established that ultraviolet (UV) solar radiation is the 
greatest single risk factor for the development of KC (Madan et al., 2010).  UVB (290–
320 nm) is considered more carcinogenic than UVA (320–400 nm) as it is completely 
absorbed in the skin and results in the mutation of tumour suppressor genes (Gailani et 
al., 1996). UVA which penetrates deeper than UVB also plays a role as it activates the 
signal transduction molecule protein C- kinase, and also impairs the activity of tumour 
suppressor T-cells leading to tumour expansion and a failed immune response (Matsui & 
DeLeo, 1991; Nghiem et al., 2002). Cumulative sun exposure may be more causally 
related to the development of SCC in that it results in UV-induced DNA damage and 
subsequent p53 gene mutations (Lee & Miller, 2009; Madan et al., 2010).  Mutations of 
the p53 gene can also be found in up to 50 percent of BCCs (Rubin et al., 2005). In 
contrast to SCC, intense intermittent recreational sun exposure (i.e., resulting in sun 
burns) and exposure during childhood may be more central to the development of BCCs 
(Lee & Miller, 2009; Madan et al., 2010).  BCCs frequently demonstrate mutations of 
chromosome 9q resulting in Patched (PTCH) gene mutations and subsequently induced 
hedgehog (Hh) signalling (Lee & Miller, 2009). It is this hedgehog signalling pathway 
that is targeted by the systemic Hh inhibitors Vismodegib and Sonidegib  – FDA 
approved for the treatment of advanced BCC (Chen et al., 2016; Sekulic et al., 2012).  
Other risks factors for the development of KC appear in Table 2.1. 
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Table 2.1:  Risk factors for the development of Keratinocyte Carcinomas* 
Risk Factor: 
 UV radiation (sun exposure, tanning beds) 
 Ionizing radiation 
 Immunosuppression 
 Human Papillomavirus 
 Smoking 
 Chronic scarring / inflammation 
 Exposure to polycyclic hydrocarbons 
 Phototherapy with psoralens (PUVA therapy) 
 Photosensitising drugs (i.e., Fluoroquinolones) 
 Arsenic ingestion 
Syndromes: 
 Xeroderma Pigmentosum 
 Oculocutaneous albinism 
 Nevoid BCC syndrome/Gorlin Syndrome/Basal cell nevus syndrome 
 Epidermodysplasia verruciformis 
 Dystrophic epidermoylsis bullosa 
 Muirre-Torre syndrome 
 KID (keratosis, icthyosis, deafness) 
 Fanconi anemia 
 Rothmund-Thompson syndrome 
 Werner syndrome 
Note. Risk factors and syndromes that increase the risk of developing Keratinocyte 
Carcinoma. (*Adapted from Lee & Miller, 2009 and Madan et al., 2010). 
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Clinical Features and Work-Up 
Common clinical features of Keratinocyte Carcinomas appear in Table 2.2.  Due 
to the relationship of KCs and UV light exposure, these lesions occur most
frequently in the head and neck region.   Of the KCs, approximately 75% are BCCs and 
25% are SCCs.   
 
Table 2.2:  Common Clinical Features of Keratinocyte Carcinomas* 
Red Flags:  
 A new rapidly growing lesion 
 A lesion that is changing in size or shape 
 A non-healing sore 
Nonspecific features that may be seen in Keratinocyte Carcinoma: 
 Nodular growth 
 Irregular border 
 Elevation 
 Erosion, ulceration, crust 
 Bleeding 
 Erythema with sharp borders 
Features suggestive of Basal Cell Carcinoma:   
 Translucent (pearly or waxy) appearance 
 Telengiectasias (fine, tortuous vessels visible near the surface) 
 Raised (“rolled”) border 
 Pigment without a netlike pattern 
 Scar like appearance 
 Erythema with pinpoint erosions 
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Features suggestive of Squamous Cell Carcinoma:  
 Adherent scale or crust 
 Cutaneous horn 
 Extensive erosion of tissue 
Note. Common clinical features of Keratinocyte Carcinomas including those that may be 
more suggestive of BCC and SCC. (*Adapted from Albert & Weinstock, 2003) 
 
Basal Cell Carcinoma 
BCCs are clinically categorized as nodular, superficial, and infiltrative or 
sclerosing subtypes (see Figures 2.1 – 2.7). Nodular BCCs are most common and present 
as waxy raised papules or nodules with telengiectasias (see Figure 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Superficial BCCs grow horizontally and present as thin erythematous plaques 
with variable scale and telengiectasias (see Figure 2.2).  
Figure 2.1:  Nodular BCCs: Left upper lip nodular pigmented BCC (a) and nodular BCC of the right 
ala (b).  
 
a. b. 
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Sclerosing BCCs are ill-defined, indurated red or white plaques that can be 
slightly elevated or depressed and atrophic (see Figure 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2:  Superficial BCCs: Superficial pigmented BCC of the scalp (a) and a large superficial BCC of 
the right temple (b) 
Figure 2.3:   Sclerosing BCCs: the forehead (a) and the right neck (b) 
a. b. 
a. b. 
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Cutaneous Squamous Cell Carcinoma 
Invasive SCC of the skin frequently presents as an erythematous, keratotic papule, 
plaque, or nodule occurring in a background of actinic damage (see Figure 2.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These can demonstrate ulceration and patients will often describe a history of an 
intermittently bleeding and non-healing sore.  Actinic Keratosis and Bowen’s Disease 
(SCC in situ) are considered precursor lesions to invasive SCC and frequently present as 
a well-demarcated erythematous, scaly plaque (Albert & Weinstock, 2003). 
Figure 2.4:  Cutaneous SCCs: the scalp (a), the left cheek (b), left ear (c), and left temple/cheek (d).   
a. b. 
c. d. 
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Management 
Biopsy. Any clinically suspicious lesion should be biopsied.  While multiple 
biopsy techniques have been advocated, a 3 mm full-thickness punch biopsy provides the 
greatest histologically diagnostic information and is thus recommended for any 
suspicious lesion.   Diagnostic imaging is reserved for clinically aggressive lesions to 
determine the extent of invasion or to help evaluate for distant metastasis on the basis of 
clinical suspicion or clinically palpable adenopathy. It is important to recognize that SCC 
of the lip is considered an oral cancer and accordingly requires clinical and prudent 
radiographic evaluation of regional lymphatics.   
Resection of the Primary Malignancy.  The primary goal in the treatment of 
BCC and SCC is to cure the patient of their malignancy while limiting both tumour and 
iatrogenic morbidity.   Further to these goals, the National Comprehensive Cancer 
Network (NCCN) provides Clinical Practice Guidelines for the evaluation and 
management of Non-Melanoma Skin Cancers.  These guidelines are up-to-date and 
established by group consensus based on currently available evidence.  Guidelines are 
available at www.NCCN.org (National Comprehensive Cancer Network [NCCN], 2019a, 
2019b). 
As the majority of cutaneous malignancies occur in the head and neck region our 
discussion will focus on cutaneous malignancies arising in this area.  The treatment of 
BCCs and SCCs is guided principally by the risk of local recurrence and/or disease 
progression.   The NCCN indicates that within the head and neck, non-melanoma skin 
cancers that are most likely to recur present in the central face, are  >1 cm in diameter, 
are clinically poorly defined, recurrent lesions, occur in areas of previous radiation, or 
   
 
 14 
occur amongst patients that are immunosuppressed.    In the case of SCC, tumours >6 
mm in the central face, rapidly growing tumours, or those that demonstrate neurologic 
symptoms (i.e., anaesthesia, motor dysfunction) are also considered high-risk (NCCN, 
2019a).   
For high-risk BCCs and SCCs (with no evidence of metastasis) the NCCN 
recommends management via Mohs micrographic surgery, resection with complete 
circumferential margin assessment (i.e., intraoperative frozen section analysis), standard 
excision with wide margins (4-6 mm) and post-operative margin assessment, or radiation 
therapy for non-surgical candidates (NCCN, 2019a).  For standard surgical excision, 
Wolf and Zitelli (1987) demonstrated that for well-defined BCCs less than 2 cm in 
diameter, excision with 4 mm clinical margins resulted in complete removal in more than 
95% of cases.   Wider surgical margins are recommended for SCCs whereby high-risk 
SCCs measuring <1 cm, 1-1.9 cm, or >2 cm in diameter require clinical margins of 4, 6, 
and 9 mm, respectively, when treated via standard surgical excision with post-operative 
margin assessment (Brodland & Zitelli, 1992). 
As per the NCCN guidelines, low-risk BCCs and SCCs can be managed via 
electrodessication and curettage (excluding terminal hair-bearing areas) or via standard 
excision with 4-6 mm margins and post-operative margin assessment (NCCN, 2019a, 
2019b).  For non-surgical candidates radiation therapy is recommended.   
Incomplete Excisions and Aggressive Features on Pathology.   Re-excision via 
Mohs micrographic surgery or resection with complete circumferential margin 
assessment (i.e., intraoperative frozen section analysis) is recommended for any BCC or 
SCC that has been incompletely excised in the head and neck region (NCCN, 2019a, 
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2019b).   For those patients that are non-surgical candidates, or amongst those lesions 
where further surgery is not possible, radiation therapy is recommended (NCCN, 2019a, 
2019b).   Adjuvant radiation therapy is also recommended for BCCs or SCCs 
demonstrating perineural or lymphovascular involvement (NCCN, 2019a, 2019b).  
Advanced Disease.  Patients presenting with advanced BCCs or SCCs including 
those with regional lymphatic involvement benefit from evaluation and management by a 
multidisciplinary tumour board. NCCN guidelines at www.NCCN.org provide direction 
with respect to the management of advanced keratinocyte carcinomas. 
The incidence of metastatic BCC ranges from 0.0028 to 0.55 percent. Systemic 
therapy in the form of Hedgehog (Hh) pathway inhibitors (i.e., Vismodegib, Sonidegib) 
can be considered amongst any patient presenting with nodal or distant metastatic BCC 
(NCCN, 2019a).  This is also a treatment option for patients with recurrent BCC 
following resection and adjuvant radiation, or amongst patients who are not candidates 
for either surgery or radiation (NCCN, 2019a). 
Metastatic SCC of the skin occurs with an incidence of approximately 2 to 6 
percent (Mokhtar, 2009).  The lip and ear represent the sites at highest risk for metastasis 
in primary SCC with an incidence of 10 to 14 percent (Mokhtar, 2009).  It is important to 
note that recurrent SCC has a 30% incidence of metastasis emphasizing the need for 
adequate primary control. Neck dissection and adjuvant radiation therapy is 
recommended for SCCs with regional lymph node involvement and the extent of 
dissection is dependent on lymph node size, lymph node number, and node location (i.e., 
parotid, ipsilateral neck, contralateral neck) (NCCN, 2019b).  Concurrent systemic 
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chemotherapy is recommended for any patient demonstrating extracapsular extension of 
tumour on lymphadenectomy (NCCN, 2019b).   
Less Common Non-Melanoma Skin Cancers 
Merkel Cell Carcinoma 
Merkel Cell Carcinoma (MCC) is an uncommon cutaneous neuroendocrine 
carcinoma. While it remains relatively uncommon, the annual incidence has risen 5-fold 
over the past 30 years (Tetzlaff & Nagarajan, 2018).  In 2011, the incidence in the United 
States was 7.9 cases per 1 million persons (Tetzlaff & Nagarajan, 2018).  MCC primarily 
affects Caucasian men at sites of chronic sun exposure in their 7th to 9th decade of life.  
Immunosuppression is also considered a major risk factor for the development of MCC 
(Tetzlaff & Nagarajan, 2018).  MCC is an aggressive malignancy with a five year 
survival rate of 50.6% for those with primary disease, 35.4% for those with regional 
lymph node involvement, and 13.5% for those with distant metastases (Harms et al., 
2016). 
The cell of origin of MCC is unknown and potentially includes epidermal stem 
cells, B-cells, and fibroblasts.   A novel human polyomavirus named Merkel Cell 
Polyomavirus (MCPyV) can be detected in 60-80% of Merkel Cell Tumours (Feng et al., 
2008).  MCPyV works through a variety of mechanisms resulting in inhibited tumour 
suppressor function and carcinomatous cellular proliferation (Tetzlaff & Nagarajan, 
2018). 
Clinical Features and Work-Up.  MCC presents as an asymptomatic, rapidly 
growing, firm, red, pink, purple, or skin-coloured nodule (see Figures 2.13 – 2.15) (Heath 
et al., 2008).  Heath and colleagues proposed the AEIOU acronym to represent lesions 
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that are Asymptomatic and Expanding rapidly amongst Immunosuppressed fair skin 
individuals Older than 50 years at UV-exposed sites (Heath et al., 2008).  In spite of 
awareness of MCC and clinical vigilance its varied appearance results in most MCCs 
being diagnosed histopathologically on biopsy when differentiated from other small blue 
cell tumours on positive cytokeratin 20 (CK20) and negative thyroid transcription factor 
1 (TTF-1) immunohistochemistry – differentiating it from small cell lung cancer.  At time 
of presentation, 65% of patients present with local disease, 26% of patients present with 
regional lymph node metastases, and 8% present with distant metastases (Tetzlaff & 
Nagarajan, 2018).  
 
 
 
 
 
 
 
Management.  Work-up and management is guided by the most up-to-date 
NCCN guidelines available from www.NCCN.org (NCCN, 2019c).  The authors 
recommend diagnostic imaging to evaluate for regional lymph node involvement and 
distant metastasis for any patient diagnosed with MCC.  For patients presenting with 
Figure 2.5:  Merkel Cell Carcinomas: the left cheek (a), left forehead (b), and right 
upper eyelid (c) 
a. b. c. 
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clinically palpable lymph nodes, these should be biopsied via fine needle aspiration 
biopsy (FNAB) or core biopsy.  Evaluation by a multidisciplinary tumour board should 
be strongly considered.   
The latest NCCN guidelines recommend sentinel lymph node biopsy (SLNB) 
prior to definitive surgical excision (NCCN, 2019c).   One third of patients presenting 
with clinically negative lymph nodes are found to have micrometastases on SLNB 
(Santamaria-Barria et al., 2013).  Recurrence occurred in 56% of SLNB-positive and 39% 
of SLNB-negative patients (Santamaria-Barria et al., 2013).  It is important to note that 
SLNB is less consistent in the head and neck region due to variability in nodal drainage 
which can result in a false-negative SLNB (Willis & Ridge, 2007). SLNB does however 
remain useful in guiding the dose and region of adjuvant radiation which is recommended 
for all patients with MCC except perhaps for those presenting in immunocompetent 
patients with <1 cm lesions that have been widely excised with no lymphovascular or 
perineural invasion.    
Once SLNB has been performed, the primary tumour requires resection with 1 to 
2 cm margins to the investing fascia as recommended by the National Comprehensive 
Cancer Network (2019c).  In the head and neck region this is typically best performed via 
Mohs surgery, modified Mohs surgery, or complete circumferential peripheral and deep-
margin assessment (NCCN, 2019c).   Neck dissection should be considered for any 
patient presenting with regional lymph node involvement diagnosed on FNAB, core 
biopsy, or SLNB – these patients require evaluation by a multidisciplinary tumour board 
(NCCN, 2019c).   Radiation to the primary site and involved nodal basin is recommended 
for any patient with nodal involvement (NCCN, 2019c).  
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Radiation therapy is recommended for the majority of patients presenting with 
MCC in an adjuvant fashion to the primary tumour site (NCCN, 2019c).   For patients 
with head and neck region MCC, radiation to the nodal basin should be considered even 
amongst those with negative SLNB due to the aforementioned risk of a false-negative 
result.   These recommendations are based on the NCCN guidelines (2019c) which 
indicate that adjuvant radiation therapy decreases local recurrence and significantly 
improves overall survival.  
Adnexal Carcinomas of the Skin 
Adnexal carcinomas are rare with an annual incidence of approximately 1 per 20 
million persons in the United States (Blake et al., 2010).  While rare, the incidence of 
these tumours has tripled over the past 30 years (Blake et al., 2010).  Similar to Merkel 
Cell Carcinoma, adnexal carcinomas occur most frequently amongst elderly Caucasian 
males.   This category of tumour includes carcinomas of the eccrine and apocrine glands, 
carcinomas of the hair follicle, and carcinomas of the sebaceous glands.  Our review of 
these lesions will focus on those most frequently affecting the head and neck region and 
appear summarized in Tables 2.3 – 2.5.   
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Table 2.3:  Eccrine and Apocrine Gland Carcinomas* 
 
 Common 
Site 
Gender Decade Clinical 
Features 
Keep in Mind Management 
Mucinous carcinoma Face / 
Eyelid 
F>M 3rd – 8th Asymptomatic, 
slow-growing, 
flesh coloured 
soft/spongy 
nodule.  
*R/O metastatic 
mucinous 
carcinoma from 
breast or GI tract. 
Standard surgical 
excision or MMS. 
Microcystic Adnexal 
Carcinoma 
Face / 
Upper lip 
F>M 6th Slow growing 
neoplasm. 
Indurated firm 
plaque or 
discrete nodule. 
Yellowish to 
flesh coloured.   
Epidermal 
surface is 
smooth or 
crusted. 
Perineural 
invasion is 
common 
Standard surgical 
excision or MMS for 
the primary tumour.  
RT +/- Chemotherapy 
with perineural 
invasion. 
Adenoid cystic carcinoma Scalp F>M 5th Asymptomatic 
crusted 
verrucous 
plaque or deep 
seated nodule. 
Perineural 
invasion is 
common 
MMS or resection 
with complete 
circumferential 
margin assessment for 
the primary tumour.  
RT for perineural 
invasion.  
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Acrospirocarcinoma Face F>M >5th Large , 
ulcerated mass 
or nodule or an 
infiltrative 
plaque 
Frequently 
metastasize to 
regional lymph 
nodes + distant 
sites 
Standard surgical 
excision + Sentinel 
node biopsy or neck 
dissection. 
Cylindrocarcinoma Scalp F>M >5th Typically arise 
from a pre-
existing 
cylindroma with 
associated rapid 
growth, 
tenderness, 
ulceration, 
discoloration 
and/or bleeding.  
Aggressive 
tumours 
Standard surgical 
excision or MMS for 
the primary tumour.  
RT for metastatic 
disease or inoperable 
tumours. 
Syringocystadenocarcinoma 
papilliferum 
Scalp M=F 6th Exophytic 
verrucous 
plaque or 
nodule. 
Metastasis is rare. Standard surgical 
excision or MMS for 
the primary tumour.  
Key.  M= Male, F=Female, RT= Radiation therapy, MMS = Mohs micrographic surgery. 
Note.  Eccrine and apocrine gland carcinomas (*Adapted from Walsh & Santa Cruz, 
2011) stratified by area of involvement, gender, age at incidence, clinical features, 
notable features and management.   
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Table 2.4:  Carcinomas of the Hair Follicle* 
 
 Common 
Site 
Gender Decade Clinical Features Keep in Mind Management 
Tricholemmommal 
carcinoma 
Head & 
Neck 
M>F 70th Slow growing 
papule or nodule. 
Metastasis is 
rare. 
Conservative 
standard surgical 
excision or MMS 
Proliferating/malignant 
tricholemmal cystic 
carcinomas 
Scalp F>M 6th Longstanding 
subcutaneous mass 
that has grown 
rapidly. Firm, 
painless nodule with 
overlying alopecia 
or ulceration. 
Aggressive 
tumours with a 
high rate of 
metastasis 
Standard surgical 
excision with wide 
margins or MMS 
for the primary 
tumour. Neck 
dissection, RT, and 
chemo has variable 
to limited success 
for disseminated 
tumours. 
Matrical carcinoma / 
Malignant pilomatricoma 
Head & 
Neck 
M>F 4th Slow growing, firm, 
non-tender nodule. 
Clinically mistaken 
as a benign 
pilomatricoma or 
inclusion cyst. 
Metastasis is 
common. 
Standard surgical 
excision with 0.5-
1cm margins or 
MMS.  RT for 
metastatic disease 
or inoperable 
tumours. 
Key. M= Male, F=Female, RT= Radiation therapy, MMS = Mohs micrographic surgery. 
Note. Carcinomas of the hair follicle (*Adapted from Walsh & Santa Cruz, 2011) 
stratified by area of involvement, gender, age at incidence, clinical features, notable 
features and management. 
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Table 2.5:  Carcinomas of the Sebaceous Glands* 
 
 Common Site Gender Decade Clinical 
Features 
Keep in Mind Management 
Sebaceous carcinoma Head & Neck, 
Eyelid 
M>F 70th Slow growing 
firm subcutaneous 
nodule with 
occasional 
ulceration.  
Yellow hue is 
common at 
extraocular sites.  
Classified as 
ocular or 
extraocular. 
Associated with 
Muir-Torre 
Syndrome 
(especially if 
diagnosed in 
younger patients). 
Can metastasize. 
Standard surgical 
excision with wide 
margins or MMS 
for the primary 
tumour.  Sentinel 
node biopsy may be 
useful for poorly 
differentiated and 
ocular lesions. 
Key. M= Male, F=Female, RT= Radiation therapy, MMS = Mohs micrographic surgery. 
Note: Carcinomas of the sebaceous glands (*Adapted from Walsh & Santa Cruz, 2011) 
stratified by area of involvement, gender, age at incidence, clinical features, notable 
features and management.   
 
Sarcomas of the Skin 
Sarcomas of the skin are a broad group of rare non-epithelial primary skin 
neoplasms.  These cutaneous neoplasms are classified according to the mature cell type 
they resemble.  We will focus on three of these neoplasms: the most common sarcoma of 
the skin – dermatofibrosarcoma protuberans (DFSP), and the most common cutaneous 
sarcoma of the head and neck - atypical fibroxanthoma (AFX), and the most common 
vascular sarcoma of the head and neck - cutaneous angiosarcoma (AS) of the face and 
scalp.     
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Dermatofibrosarcoma protuberans (DFSP).   
DFSP is the most common sarcoma of the skin.  Its annual incidence has been 
estimated at 4.5 cases per 1 million persons in the United States making DFSP nearly half 
as common as Merkel Cell Carcinoma (Criscione & Weinstock, 2007).  Unlike other rare 
skin malignancies this tumour most frequently occurs in the 2nd to 5th decade of life and 
affects individuals of African American heritage twice as frequently as Caucasians 
(Criscione & Weinstock, 2007; Rouhani et al., 2008). 
DFSP is a low-grade sarcoma of fibroblast origin.  DFSP is characterized by a 
translocation between chromosomes 17 and 22 resulting in the overexpression of platelet-
derived growth factor receptor β (McArthur, 2004).  It is differentiated from a common 
dermatofibroma on immunohistochemistry where it is positive for CD34 and negative for 
factor XIIIa. Given the characteristically slow growth of these lesions, they typically 
present as large tumours.  Microscopically, many deep finger-like projections are present 
resulting in indistinct borders and recurrence rate as high as 60% (Reinstadler & Sinha, 
2012; Stojadinovic et al., 2000).  Metastatic disease is uncommon.   
Clinical Features and Work-up.  Dermatofibrosarcoma protuberans typically 
presents as a slow growing flesh-coloured or pink nodular lesion of the trunk or 
extremities.  Presentation in the head and neck is rare.  Over time the tumour develops a 
more protruberant appearance.  The latest NCCN guidelines (2019d) recommend a deep 
subcutaneous punch or incisional biopsy as superficial biopsies may mistakenly suggest 
the lesion is a benign dermatofibroma (NCCN, 2019d).   Given the low rate of metastasis 
imaging is not routinely performed.  The NCCN suggests MRI imaging if extensive 
extracutaneous extension is suspected (NCCN, 2019d).    
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Management.   Management is directed by the most recent NCCN guidelines 
available from www.NCCN.org (NCCN, 2019d).   Mohs micrographic surgery or 
surgical excision down to the level of investing fascia with 2-4 cm peripheral margins is 
recommended with subsequent complete circumferential margin assessment (i.e., 
intraoperative frozen section analysis) (NCCN, 2019d).   Re-resection is recommended 
should final pathology demonstrate positive margins (NCCN, 2019d).    Given the 
characteristic microscopic extension of DFSP, undermining and/or flap reconstruction 
should only be considered once all margins have been histologically cleared (NCCN, 
2019d).   Radiation therapy and consultation with a multidisciplinary tumour board 
should be considered amongst patients with recurrent disease or where complete surgical 
excision is not possible (NCCN,2019d).   Chemotherapy can be considered in the rare 
event of metastatic disease and multidisciplinary tumour board consultation is 
recommended in this circumstance (NCCN, 2019d).    
Atypical Fibroxanthoma 
Atypical fibroxanthoma (AFX) is a very rare low-grade sarcoma of fibroblastic 
origin.  It typically presents in the head and neck region amongst Caucasian males in their 
7th decade of life (Ang et al., 2009; Reinstadler & Sinha, 2012).  Similar to other 
cutaneous malignancies, AFX presents with increased frequency amongst 
immunosuppressed patients. As AFX typically occurs in areas of chronic UV exposure, a 
history of previous keratinocyte carcinomas is common, and frequently the AFX is 
misdiagnosed clinically as a keratinocyte carcinoma.  Due to the rarity of the tumour 
there is no incidence data (Reinstadler & Sinha, 2012).  
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Similar to Keratinocyte carcinomas, AFX is believed to arise form UV induced 
mutations of the p53 tumour suppressor gene (Dei Tos et al., 1994).  AFX is 
histologically similar to other spindle cell neoplasms such as cutaneous malignant fibrous 
histiocytoma (MFH).  The distinction between AFX and MFH has been controversial and 
in 2002 the World Health Organization recommended the term MFH be replaced by 
Undifferentiated pleomorphic sarcoma (UPS) – AFX is considered a distinct pathological 
diagnosis to UPS (Bowles et al., 2011). In contrast to AFX, UPS is considered a 
diagnosis of exclusion and typically presents as an aggressive subfacial mass of the 
extremities amongst older adults.  UPS is discussed herein as previous reports of 
aggressive AFX lesions may have been incorrectly categorized and would now be 
considered UPS.  
Clinical Features and Work-Up.  AFX typically presents as a slow growing 
ulcerated nodule, and as previously mentioned, clinically resembles keratinocyte 
carcinoma.   On histopathology the lesion is typically confined to the dermis and thus has 
limited metastatic potential (Bowles et al., 2011).  More aggressive features on 
histopathology raise suspicion that the lesion may be an alternative sarcoma such as UPS.  
AFX is a diagnosis of exclusion on immunohistochemical analysis and is negative for 
S100 protein, cytokeratins, and desmin, differentiating it from melanoma, SCC, and 
leiomyosarcoma (Bowles et al., 2011).  
Management.  Mohs micrographic surgery or surgical excision down to the level 
of investing fascia with 1-2 cm peripheral margins is recommended with subsequent 
complete circumferential margin assessment (i.e., intraoperative frozen section analysis).  
The recurrence rate is approximately 10% for wide local excision and may be lower with 
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Mohs micrographic surgery (Reinstadler & Sinha, 2012).  To reiterate, nodal or distant 
metastasis do not occur with AFX and these findings suggest a more aggressive soft 
tissue sarcoma.   
Angiosarcomas 
Angiosarcomas are very rare vascular sarcomas that include cutaneous 
angiosarcoma of the face and scalp.  This lesion is considered a high-grade angiosarcoma 
and most frequently presents at the scalp or forehead amongst Caucasian men in their 7th 
decade of life (Holden et al., 1987).   These lesions are highly aggressive and often 
multicentric with a high metastasis, recurrence, and mortality rate.   Prognosis is poor 
with perhaps 12% of patients surviving five or more years (Holden et al., 1987)h.    
Vascular endothelial growth factor (VEGF) is involved in the regulation of 
endothelial cell proliferation, and VEGF-D levels are significantly elevated amongst 
patients with cutaneous angiosarcoma of the face and scalp (Mendenhall et al., 2006).  
Clinical Features & Work Up.  Cutaneous angiosarcoma of the face and scalp 
presents as an ill-defined bruise-like lesion (similar to a hematoma) or as broad facial 
edema - especially of the eyelids with minimal erythema (Sangeuza & Requena, 2011).  
Induration and ulceration may occur amongst more advanced lesions with some lesions 
presenting multifocally (Sangeuza & Requena, 2011).    
Tissue sampling can demonstrate immunohistochemical positivity for the 
endothelial markers CD34 and CD31, as well as, positive vascular endothelial growth 
factor receptor-3 (VEGFR-3), podoplanin, and the proliferation marker K-67 (Orchard et 
al., 1996).  Tissue biopsies of the periphery of the lesion with testing for the 
aforementioned immunohistochemical markers can help determine the extent of the 
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tumour (Sangeuza & Requena, 2011).  Given the vascular origin of the tumour and the 
high propensity for metastasis, imaging of regional lymph nodes and screening for distant 
metastases is prudent.   
Management.  Ideal treatment involves wide excision of the lesion with 
subsequent complete circumferential margin assessment (i.e., intraoperative frozen 
section analysis) and adjuvant radiotherapy (Sangeuza & Requena, 2011).  This is 
frequently not possible due to wide extension at the time of diagnosis.  Thus, primary 
radiation and potentially adjuvant systemic chemotherapy may be the only treatment 
option.  Nevertheless, referral to a multidisciplinary tumour board is recommended.   
Summary 
Non-melanoma skin cancers are an extensive group of malignancies.  The most 
common malignancy is BCC and is fortunately one of the least aggressive and best 
managed of the group. The first priority in managing any cutaneous malignancy is 
ensuring a complete removal with pathologically clear resection margins.  This removal 
will undoubtedly result in a facial defect that requires some form of reconstruction to 
minimize disfigurement.  While some reconstructions result in objectively well-
camouflaged scarring, it is the patient’s perception of the scar that matters most to their 
overall wellbeing (Brown et al., 2010).  The next chapter will focus on the impact of a 
facial scar through the lens of the World Health Organization’s International 
Classification of Functioning, Disability, and Health (ICF) (Stephens, 2001). 
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Chapter 3: ICF and Skin Scarring 
The International Classification of Functioning, Disability, and Health (ICF) 
(Stephens, 2001) is a framework for the cataloguing and description of health conditions 
and their associated impairments.  The ICF strives to integrate the medical model of 
focusing on an illness or impairment of a bodily structure or function as a medical 
condition with the more contemporary biopsychosocial model of health (Engel, 1977).  
By utilizing the biopsychosocial model, it allows for the contextualization of the medical 
condition and recognizes the unique psychosocial impact and resultant activity 
limitations/participation restrictions that can occur to a particular individual as a result of 
the medical condition.   For example, focusing medically on a benign facial scar may 
ignore its potential psychological ramifications and the degree to which it prevents an 
individual from participating in social activities.  The ICF framework strives to provide a 
more wholistic lens from which we can better understand the true impact of a health 
condition.   While this framework succeeds in describing many health conditions, it is not 
without its own limitations.  To this author’s knowledge, no previous investigations have 
utilized the ICF framework for describing the health condition or functional impairments 
of skin scarring (i.e., congenital, post-traumatic, or postsurgical scarring).  The goals of 
this chapter are to explore the current application of the ICF model to skin scarring, 
highlight previous investigations that apply the principles of ICF framework to skin 
scarring, and define areas for future investigation. 
Skin Scarring through the ICF model 
The ICF describes skin scarring as an impairment in the “repair functions of the 
skin” (b820) – “Functions of the skin for repairing breaks and other damage to the skin” 
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(Stephens, 2001).  This description highlights physiologic dysfunctions of scar formation 
– i.e., the “functions of scab formation, healing, scarring; bruising and keloid formation” 
(Stephens, 2001). This description captures the underlying impairment in body function 
(dysfunction in skin healing physiology) that produces most clinically obvious scars (i.e., 
overabundant wound healing resulting in an overgrown/hypertrophic/keloid scar).  Where 
this description falls short is in classifying clinically obvious scars resulting from 
“normal” wound healing physiology (i.e., a poorly placed/obvious scar, a scar with 
uneven texture, a scar with visible surgical markings/suture marks, etc.).  To this end, the 
ICF applies the body structure classification whereby the “skin of the head and neck” can 
be identified to have a structural impairment (s8100) (Stephens, 2001).  Thus, the ICF 
model can define the health condition of an obvious scar as an impairment of body 
function (i.e., a scar resulting from dysfunctional physiology) or simply based on its 
presence and subsequent structural impairment of the head and neck region.   
Although the ICF succeeds at identifying the presence or absence of an 
impairment in body structure or function, it is limited in its ability to stratify these 
impairments with respect to severity.  Current qualifiers within the ICF stratify 
impairments in body structure or function as being “no, mild, moderate, severe, or 
complete” problem(s) (Stephens, 2001).  This certainly applies in some circumstances 
(i.e., complete impairment in this use of one’s left hand), but is limited in its ability to 
accurately convey more subtle impairments (i.e., a slightly obvious 2cm forehead scar).  
The degree to which an impairment exists undoubtedly influences the extent to which it 
causes an activity limitation and/or participation restriction.  Thus, the ability to 
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accurately stratify the degree of impairment is paramount to effective clinician 
communication and outcomes research.  
Contemporary Objective Scar Evaluation 
The scar literature presents numerous methods for objectively evaluating skin 
scarring.   Briefly, current scar evaluation scales include: the Vancouver Scar Scale 
(Baryza & Baryza, 1995), Patient and Observer Scar Scale (Draaijers et al., 2004), 
Manchester Scar Scale (Beausang et al., 1998), Stony Brook Scar Evaluation Scale 
(Singer et al., 2007)  and the SCAR Scale (Kantor, 2016).  Although these scales 
generally demonstrate excellent reliability, they force the evaluation of scar dimensions 
(i.e., scar colouration) into categories (i.e., normal, pink, red, purple), or along a linear 
equal-appearing interval ordinal scale (i.e., 0 to 10).  While categorical and linear scaling 
may be appropriate for particular scar features, they fail to allow for scaling minor scar 
differences – for example how would one categorically scale a scar that is normal with 
some pink components.   These scales also fail to quantify abstract features – for 
example, it would be challenging to apply a numeric scale indicating the degree to which 
a scar might distort surrounding facial structures.   Additionally, particular scar variables 
(i.e., vascularity and pigmentation) have been empirically shown to conform to 
curvilinear mathematical models (Brandt et al., 2009), and thus the use of linear ordinal 
scaling measures for these variables do not conform to their inherent mathematical 
assumptions.  Thus, although categorical and ordinal scar evaluation scales may be 
reliable, they are inherently insensitive to minor scar differences, have difficulty 
quantifying some features, and struggle with mathematical assumptions that may not 
apply to all scar variables.   These issues consequently impede the ability to classify skin 
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scars and also impair the use of these scales in clinician communications or scar 
outcomes research. 
Visual Analog Scaling 
To overcome some of the limitations of current scar evaluation scales, several 
attempts have been made to utilize visual analog scaling (Beausang et al., 1998; Singer et 
al., 2007).  Visual analog scaling employs a line of set length (i.e., 100 mm), and asks 
observers to mark where they feel a particular scalable feature falls on that line.  This 
technique does not require conformity to a particular mathematical model and has been 
previously applied in the voice assessment literature in the characterization of abstract 
voice dimensions such as voice “pleasantness” (Eadie & Doyle, 2005).  Both the 
Manchester Scar Scale (MSS) and the Stony Brook Scar Evaluation Scale (SBSES) draw 
on this scaling technique as a means of obtaining a gestalt summary score for the overall 
appearance of a scar (Beausang et al., 1998; Singer et al., 2007).  While the utility of this 
method of assessing overall scar appearance cannot be discounted, both the MSS and 
SBSES also employ additional ordinal and/or categorical scaling for independent scar 
features (i.e., colour, height, width, distortion, texture, etc.) (Beausang et al., 1998; Singer 
et al., 2007).  In striving to achieve a valid method of scar severity classification, 
independent scar features and overall gestalt measures require the use of reliable and 
methodologically valid measurement techniques.  Thus, there remains a need for the 
development of an instrument that can be employed for the universal, valid, and reliable 
classification of skin scar severity.   
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The Patient’s Perspective 
In addition to the aforementioned limitations of clinical scar outcome/assessment 
measures, few scar scales include the patient’s own perspective on their scar (Durani et 
al., 2009; Idriss & Maibach, 2009).  As described earlier, the limitations and restrictions 
posed by a scar are based primarily on the individual’s self-perceived severity of their 
scar (Brown et al., 2010). A recently developed patient reported outcome (PRO) 
instrument – the SCAR-Q – has been validated by Klassen and colleagues (2018) to 
address this limitation (Klassen et al., 2018). This tool will help further elucidate the 
patient specific outcomes that can be combined with objective scar assessment to yield a 
more comprehensive understanding of scar severity and its biopsychosocial impact.   
Social Impairment 
Notwithstanding the importance of defining the severity of impairment in body 
structure and/or function, the ICF seeks to determine the resultant activity limitations 
and/or participation restrictions caused by this impairment.  To this end, contemporary 
research has largely focused on defining the impact of facial scarring on social 
interactions (Kapp-Simon, 1986; Pillemer & Cook, 1989; Pope & Ward, 1997; Rumsey et 
al., 2004), quality of life (Bock et al., 2006) and psychological well-being (Brown et al., 
2010; Love et al., 1987; Malt & Ugland, 1989; Ramstad et al., 1995; Rumsey et al., 2004; 
Sobanko et al., 2015; Tebble et al., 2006).  The majority of this research focuses on 
children and adolescents with congenital craniofacial abnormalities resulting in facial 
disfigurement (i.e., Tessier clefting, cleft lip, facial abnormalities associated with 
syndromes, etc.) (Kapp-Simon, 1986; Okkerse et al., 2001; Pope & Ward, 1997; Tessier, 
1976) with only a few investigations highlighting acquired facial scarring (i.e., due to 
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burns, trauma, or surgical/operative scarring) (Borah & Rankin, 2010; Brown et al., 2008; 
Ishii et al., 2009; Kim et al., 2013; Rankin & Borah, 2003; Sobanko et al., 2015; Tebble 
et al., 2006; Van Den Elzen et al., 2012). While much of the literature succeeds at 
suggesting the impact of facial scarring, to this author’s knowledge none have addressed 
this impact utilizing the framework set-forth by the ICF (Stephens, 2001). Further, very 
few investigations have specifically inquired into the activity limitations and participation 
restrictions of those with facial scarring beyond a superficial discussion of social and/or 
vocational activities (Sobanko et al., 2015).    
Summary: The Need for a Biopsychosocial Lens 
Skin scarring as a health condition identifies flaws in the medical model of health 
as this model focuses primarily on diagnosis and treatment and does not conceptualize the 
impact of the health condition on the particular individual.  As a corollary, scar 
evaluation scales have also primarily focused on individual scar features with very few 
attempts at evaluating the psychological and social impact of a scar on the affected 
individual.   The biopsychosocial model of health strives to integrate the health condition 
into an individual’s unique psychological and social context.  For example, a very visible 
facial scar in North America may be viewed as undesirable, depressing, socially isolating 
and in need of treatment, whereas the same scar in tribal Africa may be viewed favorably 
and as a sign of higher social status.    Thus, the biopsychosocial model of health works 
to contextualize the health condition for a particular individual.  It is this biopsychosocial 
model on which the ICF framework is built with the goal of providing a means for 
reviewing health conditions and their associated impairments, activity limitations, and 
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participation restrictions.  The ICF model thus provides the necessary means for a more 
comprehensive understanding of the impact of skin scars.   
The very first step in the process of applying the ICF model and understanding the 
psychological and social impacts of a scar requires an accurate and consistent means of 
evaluating skin scars.  Given the previously reviewed limitations of current scar 
evaluation scales, the development of a valid scar assessment tool is necessary. Only 
through the development of such a tool can the patient reported outcomes and 
psychological and social impact be truly understood.  Thus, the development of a novel 
valid scar evaluation scale is the focus of the next chapter.  
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Chapter 4:  Preliminary Reliability Analysis of a Novel Scale for the Objective 
Evaluation of Linear Scars 
Introduction 
Surgeons have long sought methods of achieving optimal post-operative surgical 
scars.  In spite of these efforts, no objective data exists to support scar optimization 
techniques. A longstanding challenge in establishing scar optimization techniques centers 
on the ability to objectively evaluate scars. While several scar evaluation scales have 
been proposed (Baryza & Baryza, 1995; Beausang et al., 1998; Draaijers et al., 2004; 
Kantor, 2016; Sullivan et al., 1990; Vercelli et al., 2003), they largely have been limited 
by the inconsistent application of the scales, or incorrect assumptions about how scar 
dimensions (e.g., pigmentation, vascularity, pliability, etc.) can be assessed relative to the 
inherent mathematical limitations of the scar scales themselves (Brandt et al., 2009).  
Literature Review and Critical Appraisal 
Several publications have summarized contemporary strategies for assessing 
postsurgical scars and current scar rating scales (Durani et al., 2009; Idriss & Maibach, 
2009; Perry et al., 2010; Roques & Téot, 2007; Vercelli et al., 2003).  Briefly, current 
scar evaluation scales including the Vancouver Scar Scale, Patient and Observer Scar 
Scale, Manchester Scar Scale, Stony Brook Scar Evaluation Scale, and SCAR scale 
primarily utilize categorical and/or ordinal scaling methods.  Although these scales 
demonstrate good-to-excellent between-rater and within-rater reliability, they force the 
evaluation of specific scar dimensions (i.e., pigmentation) into categories (e.g., normal, 
pink, red, purple), or characterization using a linear, equal-appearing interval ordinal 
scale (i.e., 1 to 10).  While categorical and linear scaling may be appropriate for particular 
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scar dimensions, they fail to allow for scaling minor scar differences across the full 
spectrum of scar severity.  Furthermore, particular scar variables (i.e., vascularity and 
pigmentation) have been empirically shown to conform to curvilinear mathematical 
models (Brandt et al., 2009) and, thus, the use of linear, equal-appearing interval scaling 
measures for these variables does not conform to their inherent mathematical 
assumptions.  Thus, although categorical and ordinal scar evaluation scales may be 
reliable, they tend to be insensitive to minor scar differences and are inconsistent with 
mathematical assumptions that may not apply to all scar dimensions. 
To overcome the limitations of categorical and ordinal scar scaling, several 
attempts have been made to utilize visual analog scaling (Duncan et al., 2006; Singer et 
al., 2007). Visual analog scaling employs a line of set length (i.e., 100mm), and asks 
observers to mark where they feel a particular scalable dimension falls on that line; 
absolute anchors for a given scale are provided, but in contrast to equal-appearing-
interval scales, no intrinsic value is provided to the rater.  Both the Manchester Scar Scale 
(MSS) and the Stony Brook Scar Evaluation Scale (SBSES) draw on this scaling 
technique as a means of obtaining a gestalt summary score for the overall appearance of a 
scar.  While the utility of this method of assessing overall scar appearance cannot be 
discounted, both the MSS and SBSES employ additional ordinal and/or categorical 
scaling for independent scar dimensions (i.e., colour, height, width, distortion, texture, 
etc.).  In striving to define methods to improve surgical scarring, one must employ a scar 
evaluation scale that evaluates overall scar appearance but also allows for the accurate 
evaluation of independent scar features.  As particular scar improvement strategies may 
alter unique scar dimensions independently, a valid and practical scar evaluation scale 
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must allow for the measurement of each independent variable so that one may be able to 
establish the degree that each variable plays in the overall, composite appearance of a 
scar.  Additionally, it is possible that a given dimension of a scar may carry considerably 
greater impact relative to another dimension.  Thus, the ability to measure specific 
dimensions inherent in a scar, while at the same time assessing the global characteristic of 
a scar may provide valuable clinical information on treatment change and efficacy. 
Objectives 
This investigation sought to build on the limitations of contemporary scar 
evaluation scales and generate a scar scale that could be utilized for the valid and reliable 
evaluation of independent scar dimensions, as well as, serving to document overall scar 
acceptability.  
Methods 
Participants 
Thirty-four adults (25 women, 9 men) ranging in age from 19 to 63 years (Mean: 
30 +/-1 year) served as scar observers/evaluator participants. These participant observers 
were voluntarily recruited from a population of university students and hospital 
employees (i.e., secretaries, therapists, service staff, etc.) who were naïve relative to any 
formal exposure to scars or the methods used to evaluate them. The participant observers 
included those without personal experience with surgical scarring to avoid any undue 
influence of personal bias in evaluating surgical scars as part of this project. Scar 
observers were asked to participate in a prospective, randomized evaluation of surgical 
scars using the novel scar scale software. Research ethics approval was obtained 
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(HSREB# 12501E) and informed consent was obtained from all participant observers 
prior to their participation.   
Sample size calculation 
To achieve meaningful inter-rater and intra-rater assessments, sample size 
calculation required a minimum of 23 subjects.  That is, a total sample size (N) of 23 
individuals was determined to be sufficient to detect the hypothesized effect (r ²=.12) of 
within-subject independent variable 81.6 percent of the time using a .05 alpha level, 
assuming a within-subject correlation of .30 (Lee, 2014).  This sample size was exceeded 
during the study.  
Design 
This investigation was designed as a three-phase study.  The first phase involved 
the design and development of a novel scar assessment instrument.  To allow for 
automated pilot testing, the second phase involved the development of a novel computer-
based scar evaluation program.  The third phase then utilized this novel software to allow 
for a prospective and randomized assessment of the novel scale’s reliability and validity.  
Phase 1: Scale Development.   A review by Durani et al. (2009) thoroughly 
discusses current scar scales and makes strong recommendations for the generation of a 
novel assessment instrument, including the rigorous methodology required to generate 
such an instrument (Durani et al., 2009). Based largely on these recommendations, the 
present investigation sought to generate a reliable and valid scar assessment instrument.   
The first component of generating a useful scar scale requires the establishment of 
the dimensions to be scaled.  Such features as the length, width and height of a scar are 
reasonable to consider, but these do not provide a complete description of all scar features 
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which could also include the colour of a scar, any evidence of surgery (i.e., suture marks), 
distortion of surrounding structures (i.e., the eyelid is pulled by a temple scar), etc.  To 
this end, we reviewed the literature and all contemporary scar assessment instruments in 
an effort to better understand the dimensions central to scar evaluation (Baryza & Baryza, 
1995; Beausang et al., 1998; Draaijers et al., 2004; Kantor, 2016; Sullivan et al., 1990; 
Vercelli et al., 2003).  This review established that only scar pigmentation (i.e., the colour 
of a scar) was universally scaled.  Additional quantifiable physical dimensions and 
qualitative subjective dimensions were also included in these instruments, but there was 
no consensus across these assessment instruments as to which dimensions provide the 
most descriptive information.  Given this lack of uniformity, we turned to patients and 
experts to further elucidate a reliable list of dimensions central to scar characterization 
and evaluation. 
Fifty structured qualitative patient interviews took place whereby individuals with 
a scar on the face or neck were asked about their scar and the dimensions they felt most 
accurately described it.  The patient population included any individual presenting to a 
tertiary-care skin cancer clinic for post-operative evaluation of a facial reconstructive 
procedure resulting in a facial scar (i.e., Mohs closure, scar revision, etc.).  Each patient 
was invited to voluntarily participate in this short interview. Patients were excluded from 
participation if English was not their primary language. All interviews were conducted 
independently by the primary author (MGB), whereby the author presented the purpose 
of the study and asked patients to comment on the key features that characterized their 
scar.   A list of critical, patient generated, dimensions were subsequently generated.   
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Following the determination of dimensions deemed to be important to patients, 
experts were next asked to comment on the dimensions they felt were important to skin 
scar evaluation.  A structured interview of eight Board Certified Otolaryngologist – Head 
and Neck Surgeons (varying in experience from five to twenty-five years), and ten 
clinical nurses (varying in experience from one to fifteen years), took place.  These 
interviews were conducted independently by the primary author (MGB).  Each 
interviewee was shown a series of linear scars of the face or neck varying in general 
severity and then asked to comment on the dimensions they felt were most important to 
characterize these scars.  This process generated a list of scar dimensions that were 
expert-critical. 
Next, the investigative team (MGB, CCM, PD) reviewed the patient-critical and 
expert-critical scar dimensions.  Each dimension was independently assessed for its 
relevance, clarity, and validity to the goal of the scar assessment instrument.  This 
generated a core group of dimensions.  Synonymous and similar terms for specific 
dimensions (i.e., pigmentation, colouration) were combined and the final wording of the 
dimensions to be scaled were then formulated.  It is important to recognize that while 
individual dimensions were formulated, they were not mutually exclusive which speaks 
to the complexity of scar scaling.  Nevertheless, this process resulted in a set of eight 
observer scalable dimensions (see Table 4.1). Of the eight dimensions, five were similar 
to those appearing in previously reported scales – Height, Width, Pliability, Irregularity 
and Distortion (Kantor, 2016; Vercelli et al., 2003), taxonomy was change for one 
dimension – Discolouration, and two were unique to this investigation –Evidence of 
Surgery, and Camouflage.  The descriptors/prompts for each dimension were generated 
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and agreed upon by the research team.  These dimensions were then submitted to an 
assessment of their face validity. 
 
 
Table 4.1:  Dimensions assessed in the Scar Scale  
 
Dimension Description 
Width How thick is the scar? 
Height How raised is the scar? 
Discolouration How much does the colour vary from normal adjacent tissue? 
Pliability 
How pliable does the scar appear if moved between your 
fingers? 
Irregularity How even is the scar along its course (i.e., bumpy, rough, etc.)? 
Distortion How distorted is the skin adjacent to the scar? 
Evidence of Surgery 
Are there any features that make the scar appear operated on? 
(i.e., suture marks, drain marks)? 
Camouflage How obvious is the scar? 
Note.  Scar Scale Dimension definitions.  This list was provided to all scar observers 
during their assessments. 
Face validity assessment asked a group of 30 volunteer participants (non-medical 
professionals varying in age from 23 – 64 years) and who were naïve to the goals of this 
investigation what each dimension and descriptor meant to them.  Through this process, 
the dimensions and prompts were then refined to those appearing in Table 4.1.   
Once the set of dimensions for scar evaluation were generated, we reviewed the 
literature for the best means of scaling these dimensions.   Contemporary scales were 
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found to utilize descriptor based categorical scaling, ordinal linear scaling, or visual 
analog scaling.  Descriptor based categorical scaling requires the scar evaluator to select 
the best choice from a group of predetermined, potential options (i.e., the colour of the 
scar is: 1 - Red, 2 - Pink, 3 - Blue, etc.).  This type of scaling is impractical to a useful 
scar assessment instrument as it does not afford a means of grading dimensions (i.e., the 
colour of the scar sits somewhere between pink and red and has a bluish tinge).   Given 
this important limitation, no descriptor based categorical scaling was utilized within our 
assessment scale.   
In contrast to descriptor scaling, linear ordinal scaling is a means of evaluating a 
dimension whereby an evaluator ranks the dimension using a predetermined, equal-
appearing interval scale (i.e., the redness of the scar is graded 2 out of 10). Typically, 
such scales are constructed so that one end of the scale (e.g., “1”) is normal which the 
opposite end of the scale (e.g., “10”) represents the most extreme descriptor for a given 
dimension.  The inherent limitation of utilizing a linear scale is whether the dimension 
being measured conforms to the mathematical assumptions of linear scaling.  For 
example, the dimension of length can be linearly scaled (i.e., the scar is 2 cm vs. 1 cm 
long).  A challenge occurs when one attempts to assign a linear value to a dimension that 
does not grow in a linear fashion (i.e., how much more pigmented is scar A compared to 
scar B)?  Using this example, a scaled score of 4 cannot be assumed to be half as 
pigmented as that of one that is scaled as a 2.  The underlying issue in this situation is that 
while some dimensions logically grow linearly (e.g., length), many are characterized by 
increasing changes that cannot be captured using the linear assumptions that exist for 
equal-appearing-interval scales.  This question was the basis of a previous investigation 
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by our group whereby it was experimentally determined that some dimensions do not 
conform to the assumptions of linear scaling (Brandt et al., 2009). Thus, a linear equal 
appearing interval scale was not utilized for the creation of our novel scar assessment 
instrument. 
Relative to categorical or equal-appearing interval methods of measurement, 
visual analog scaling requires an evaluator to mark where they feel the item being 
measured falls along the full spectrum of a specific dimension – visually represented as a 
line of set length between two anchor points.  To adequately scale a dimension, the 
anchor points must represent extremes for the dimension.  For example, an evaluator 
would evaluate a scar for how red it appears and then mark a point along a 10 cm line 
whereby one anchor point/end of the line indicates “no redness” and the other anchor 
point indicates “extremely red”.  The infinite choices provided by this visual 
representation of the gradient of the scale (the line) provide a means of scaling with no 
inherent limitations as to the type of dimension being scaled (i.e., whether the dimension 
is linearly quantifiable).  The most significant advantage of using VA scaling methods for 
assessment of subjective dimensions is that it is appropriate for both those types of scaled 
continua that grow linearly as well as those that do not.  Thus, VA scaling provides an 
ideal means of gathering valid measures of dimensions such as those which characterize 
surgical scars.  This type of scaling has been successfully applied to the voice perception 
literature to evaluate subjective and abstract voice dimensions such as pleasantness or 
harshness (Eadie & Doyle, 2002a, 2002b).  Given the success found in utilizing this form 
of scaling in evaluating abstract dimensions within other areas, the application of a visual 
analog scale to the realm of scar assessment is a logical and empirically supported 
   
 
 45 
progression.  As such, two contemporary scar evaluation scales utilize this as a gestalt 
summary measure of overall scar appearance with excellent reliability (Duncan et al., 
2006; Singer et al., 2007).  Given the utility of visual analog scaling and its application to 
the evaluation of subjective difficult to scale dimensions, visual analog scaling was 
chosen as the method of dimension scaling for our scar evaluation instrument.   
Phase 2: Scar Evaluation Automation.  To evaluate dimensions scaled using a 
visual analog scale, one typically measures the location of the evaluators marking along 
the defined length of the visual analog line (i.e., the evaluator puts a pen mark for 
“redness” at a point 7 cm along a 10 cm line, resulting in the score of 7 for that 
dimension).  If we measured the visual analog ranking of 8 dimensions across 48 scar 
photographs, this would require 354 ruler measurements per subject.  The application of 
this form of scaling would thus render itself impractical for the validation of a scar 
assessment instrument requiring a large volume of participants.  To meet this challenge, 
we recruited the assistance of Dr. Vijay Parsa, School of Communication Sciences and 
Disorders, Western University, Canada to facilitate the development of a computer-based 
software application (Scar Ratings Software (ScaRS)).   
The ScaRS program displays a random photo of a scar and a set of preselected, 
but randomly organized dimensions, each with their corresponding gradient lines (see 
Figure 4.1).  A moveable tab along the gradient line allows participants to scale the 
dimension in a visual analog fashion. When all dimensions have been scaled, the subject 
can move forward to the next randomly selected photo. Once all photos have been 
evaluated, the software reorganizes the images and their resultant dimension scores so 
that they can be conveniently tabulated in a spreadsheet.   
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Figure 4.1:  ScARS - Scar Rating Software 
 
Note. Screenshot of the ScaRS program developed by Dr. Vijay Parsa, PhD, Western 
University, Canada.  Scalable dimensions appear on the right. A slider allows the visual-
analog scaling of each dimension. The question mark appearing to the right of each 
dimension provides a written explanation of the dimension being scaled.   
 
Phase 3: Scar Evaluation. With a novel scar assessment scale, dimensions 
identified and defined, and a software program developed, this investigation sought to 
determine the reliability, validity, responsiveness, interpretability, and feasibility for use 
of the scale within a clinical environment.  To this end, a prospective and randomized 
evaluation took place.  
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Procedure 
Participants were asked to evaluate 40 high-resolution photos of surgical scars.  
These were obtained from a database of patient photographs.  All patients consented to 
the storage of their photos and the use of these photos for ethics approved research. The 
photos were cropped and magnified to demonstrate the scar in its entirety.  Any concealer 
make-up was removed prior to scar photography. The scars varied by location, size, 
shape, color, and presumed texture.  Scars were located on the forehead, cheek, upper lip, 
lower lip, chin, upper neck, and lower neck, and varied in length from 3 cm to 10 cm.  To 
ensure ratings were consistent and reliable, eight of the scar images - varying in severity 
(determined through a group consensus exercise), were selected as repeat images to be 
evaluated twice, resulting in a total set of 48 images.  None of the photographs 
represented “area” scars; rather, all scars were linear and the result of incisions of varied 
length.  
For each scar photo, participants were asked to rate the scar across the dimensions 
of Height, Width, Discolouration, Pliability, Irregularity, Distortion, Evidence of Surgery, 
and Camouflage using the visual analog scale.  Participants were provided with a 
description of each scar dimension through the testing software. All testing was 
performed independently using the novel ScaRS program.  Both the order of photo 
presentation and the list of scalable dimensions were randomized for each participant. 
Observers were allowed to take as much time as necessary to view the photographs and 
provide their ratings and were additionally allowed to alter their evaluations throughout 
the test.  All assessments were conducted in a quiet laboratory used for psychophysical 
research and all images were presented via a desktop computer (Sony Vaio) and high-
   
 
 48 
resolution color monitor (Samsung MultiSync 1700).  Once testing had begun, 
participants were not allowed to ask questions of the research team.  At the completion of 
testing, participants were allowed to ask questions and provide comments to the research 
team.   
Outcome Measures and Statistical Analysis 
All data analyses were performed using PSAWStatistics 18 (IBM, Minneapolis, 
MN).  Ratings across observers for each scar photograph were pooled to allow for a 
determination of the mean and variability of responses. This was done to ensure that the 
scaling procedure could evaluate and capture a wide range of scar severity.    
Cronbach’s alpha coefficient is widely understood to indirectly indicate the 
degree to which a set of items measures a single unidimensional construct. Thus, 
Cronbach’s alpha was used to evaluate between-rater/inter-rater agreement across each 
scar scale dimension for each individual photo.  For the eight scar photos with repeat 
evaluations, Cronbach’s alpha scores were also utilized to determine within-rater/intra-
rater agreement for each scar dimension. 
To better understand the influence of using this novel testing software and to 
determine the role of familiarity with the use of a visual analog scale, a second data set 
was generated whereby the ratings for first two images evaluated by each observer were 
eliminated from the data set – as the photographs were presented in random order, the 
eliminated ratings were ultimately removed in a randomized fashion.  This data set 
provided data free of any learning bias and was subsequently compared to the original 
data set that included the ratings for all the images.   
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Results 
All participants completed the evaluation task and required approximately 43 +/- 
3 minutes (Mean +/- Standard Deviation) to complete the ratings for 48 photos (inclusive 
of the 8 repeat images).  Thus, a total of 13,056 independent ratings were gathered [(# 
photos) x (# viewers) x (# dimensions)]. 
Figure 4.2 graphically demonstrates the mean rating for each of the scar photos 
across the dimensions evaluated.  This figure illustrates that the scar photographs 
demonstrated variability in the severity of the dimensions evaluated.  Table 4.2 presents 
the overall mean ratings of the scar photos for the dimensions evaluated.  This table 
illustrates the range of scar severity across the eight dimensions being evaluated.  Figure 
4.2 and Table 4.2  demonstrate variability of severity amongst the scar photos and the 
utilization of the full spectrum of the visual analog scale by the observers.  
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Figure 4.2:  Mean Scar Photo Ratings 
 
Note.  Mean rating for each dimension for each scar photo. Coloured dots represents the 
mean ratings for each scar photo for the corresponding dimension.  Possible responses 
range from 0 to 100 for each dimension. Variation in dimension ratings represents the 
spectrum of severity for each dimension across the forty-image data set.  
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Table 4.2:  Scar Photo Range of Responses 
 
Width Height Pliability Discolouration Irregularity Distortion 
Evidence 
of Surgery 
Camouflage 
Mean 23.88 15.28 33.17 34.88 26.46 24.02 30.58 45.30 
Min 3.62 3.42 13.73 5.71 3.78 3.76 5.26 4.38 
Max 75.52 53.03 57.76 73.88 68.03 64.97 92.67 88.60 
95% 
CI 
18.78; 
28.98 
11.64; 
18.93 
29.78; 
36.55 
29.42; 
40.35 
21.41; 
31.52 
19.15; 
28.89 
24.38; 
36.78 
38.08; 
52.52 
Note.  Range of responses for the overall image data set.   Values presented as mean 
rating for all images across each of the scaled scar dimensions.  Minimum, Maximum, 
and 95% Confidence Interval (CI) data is presented.    Possible responses range from 0 to 
100 millimeters for each dimension. Variation in responses represents spectrum of 
severity for each dimension across the forty-image data set.  
Within-rater / intra-rater agreement across the 8 repeated photos is presented in 
Table 4.3. These are presented as Cronbach’s alpha coefficients across the 8 repeated 
photographs.   
 
Table 4.3:  Within-rater agreement for the eight scaled dimensions 
 
Scar Dimensions Intra-rater Agreement  
Width 0.788 
Height 0.818 
Pliability 0.837 
Discoloration 0.744 
Irregularity 0.764 
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Distortion 0.796 
Evidence of Surgery 0.925 
Camouflage 0.878 
Note. Intra-rater agreements for the eight scalable dimensions presented as Cronbach’s 
alpha coefficients. 
Table 4.4 provides the between-rater / inter-rater reliability for the 8 scaled 
dimensions across the entire set of 40 photos. These are also presented as Cronbach’s 
alpha coefficients.    
 
Table 4.4:  Between-rater agreement for the eight scaled dimensions 
 
Scar Dimensions Inter-rater Agreement 
Width 0.903 
Height 0.898 
Pliability 0.904 
Discoloration 0.913 
Irregularity 0.777 
Distortion 0.937 
Evidence of Surgery 0.963 
Camouflage 0.939 
Note. Inter-rater agreements for the eight scalable dimensions presented as Cronbach’s 
alpha coefficients.   
The original data set was compared to the data set, whereby the first two ratings 
were removed (i.e., for the 40 scar photos randomly presented, the first and second photo 
data were removed) thus, providing ratings for only 38 photos. This data was evaluated to 
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determine whether unfamiliarity with a visual-analog scale influenced the ratings of scars 
across the eight scalable dimensions.  Mean ratings for the 8 scalable dimensions for the 
40 presented photographs did not vary significantly when the two data sets were 
compared.   
Discussion 
The goals of this investigation included the determination of a core set of scalable 
dimensions for the characterization of linear scars, the development of a novel scar 
evaluation scale, and the testing of a scar evaluation computer program.   
Through rigorous methodology, a core set of scar dimensions were established 
(Table 4.1).  These dimensions were derived through previously validated contemporary 
scales, interview consensus, and face validity testing. The majority of dimensions 
demonstrated strong between-rater (Table 4.4) and within-rater (Table 4.3) agreement 
amongst a set of 34 participants.  Based on these results, it appears that the dimensions 
assessed can be scaled in a reliable fashion.  While differences in the degree of 
consistency did vary by dimension, which is to be expected, overall, raters assessed each 
dimension with what would appear to be a relatively stable intrinsic metric.  In spite of 
these achievements, the dimension of irregularity was found to be the most variable 
relative to the other inter-rater correlations.  This variability was further supported by the 
routine pressing of the definition key – which provided the descriptor – “How even is the 
scar along its course (i.e., bumpy, rough, etc.)?”.  The need for viewing the definition 
suggests face- and content-validity concerns.  At the completion of the testing period, 
participants were invited to provide feedback and several participants suggested that this 
dimension title be changed to “Texture”.  During the initial dimension gathering and 
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face-validity exercise, “Texture” was indeed suggested as an alternative title to 
“Irregularity”, and thus a subsequent study will contrast these two terms to ensure 
optimal face-validity going forward.  
Post-testing feedback also elucidated an additional dimension that had been 
missed in the original dimension gathering process – the concept of scar impact.  
Participants suggested that while the scaled dimensions allowed for scar characterization, 
they neglected to capture the relevance of the scar– i.e., a small scar on the forehead may 
be considered less relevant/impactful than an identical scar of the mid-cheek.  The impact 
of scar location, its relevance to the surrounding structures, and its relevance to the face 
as a whole, are central to the concept of scar severity and thus must be included in a valid 
scar outcome measure.  Since the time of the outset of this investigation, Godoy and 
colleagues (2011) demonstrated that facial lesion size and location to impart a facial 
“attractiveness penalty” – with larger and more central facial lesions more negatively 
affecting perceived facial attractiveness (Godoy et al., 2011).  This finding is consistent 
with that identified by our scar observers, and subsequent scar scale development and 
validity testing must incorporate the concept of scar “impact” – i.e., how much of an 
influence does the scar have on the rest of the face. 
In spite of the aforementioned concerns, the scar dimensions of width, height, 
pliability, discolouration, distortion, evidence of surgery, and camouflage appear to be 
reliably and consistently evaluated using the visual-analog scaling paradigm. This testing 
paradigm improves upon the mathematical assumption limitations of previous scar 
evaluation scales (Brandt et al., 2009) while also demonstrating superior reliability (see 
Table 4.5).  Thus, the initial validation of the proposed scar dimensions and testing 
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paradigm provides empirical support for the establishment of a novel scar evaluation 
scale termed the Scar Camouflage Scale.  Planned subsequent investigations will further 
validate and refine this scale to ensure clinical reliability, while also integrating the 
findings of this investigation.  
Table 4.5 
 
Comparison of Scar Camouflage Scale to other Scar Rating Scales* 
 
Scale Year Intra-rater reliability Inter-rater reliability 
VSS 1990 
Acceptable 
(α = 0.71 – 0.79) 
Poor to  Moderate 
(ICC = 0.03 – 0.64) 
MSS 1998 N/A 
Good 
(Spearman’s 0.87) 
OSAS 2004 
Acceptable 
(α =  0.74–0.90) 
Poor to Moderate 
(ICC = 0.18–0.56) 
SBSES 2007 N/A 
Good 
(Spearman’s 0.73 to 0.85) 
SCS 2013 
Acceptable to Excellent 
(α =  0.74 – 0.92) 
Acceptable to Excellent 
(α =  0.78 to 0.96) 
*Adapted from Vercelli et al., 2003. 
Key. VSS = Vancouver Scar Scale; MSS = Manchester Scar Scale; OSAS = Observer 
Scar Assessment Scale; SBSES = Stony Brook Scar Evaluation Scale; SCS = Scar 
Camouflage Scale, ICC = Intraclass Correlation Coefficient. 
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Note.  Intra- and inter-rater reliability for contemporary scar evaluation scales.  Intra-rater 
reliability are presented as Crohnbach’s alpha. Inter-rater reliability presented as 
Intraclass Correlation Coefficient, Spearman’s coefficient, or Cronbach’s alpha.  
 
While the initial focus of this investigation sought to identify scar dimensions that 
could be scaled and subsequently develop a novel scar scale, a secondary focus was the 
development and testing of a novel scar-rating program (ScaRS program).   Participants 
reported that the software was intuitive and easy to use. Additionally, observers indicated 
that the organizational presentation of the scar photograph, along with the series of 
dimensions to be rated were easily understood and that the ability to manually adjust the 
slider on each dimensional scale facilitated their ability to rate each dimension in an 
independent fashion.  As such, they reported the ability to quantify the characteristics 
inherent to any given scar photograph without difficulty. This general finding suggests 
that the ability to employ the current software within a clinical environment is not only 
feasible, but of little burden to observers.  Furthermore, the substantial time savings of 
automated quantifying of visual-analog ratings, the unrestricted incorporation and 
manipulation of scalable dimensions, and the randomization of both the scalable 
dimensions and photographs presented, provide for an invaluable tool in the evaluation of 
scars and/or other features of photographs.   
Conclusions 
Subjective scar dimensions can be reliably measured using a visual-analog scaling 
paradigm.  The results achieved provide preliminary empirical support for the validation 
of the Scar Camouflage Scale while also suggesting direction for future investigation.  
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The ScaRS program provides an intuitive means of photographic evaluation and rating 
that can be employed in subsequent validity testing. These achievements establish a 
strong foundation for future scar evaluation, with the goal of objectively evaluating scars 
and the methods of improving them. 
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Chapter 5: Conclusions and Bringing it all Together 
 Thus far this work has highlighted the most common mechanism for acquiring a 
facial scar (i.e., skin cancer), the biopsychosocial implications of facial scarring, and the 
elements central to scar evaluation and objective scaling.    This chapter will review and 
integrate these concepts, highlight the clinical implications of this work, and discuss 
potential directions for future research.  Before concluding, a discussion of the limitations 
of the present work will be addressed.   
Skin Cancer 
Skin cancer is a common disease, so frequent that one in every three newly 
diagnosed cancers is skin cancer (Vogel, 2018).  Canadians are particular susceptible to 
this disease with Canada being ranked 19 of 62 countries relative to skin cancer 
susceptibility (Vogel, 2018).   Primarily due to direct sun exposure, the head and neck 
region is the most commonly affected area with up to 80% of skin cancers affecting this 
vital region (Subramaniam et al., 2017).  As was originally outlined, the burden of facial 
skin cancer is substantial and multifactorial on an individual and societal level.  Not only 
is an individual confronted with the anxiety provoking diagnosis of a cancer, but 
frequently the malignancy is obvious and intrinsically disfiguring resulting in social 
isolation.   Chapter 2 provides a thorough review of contemporary skin cancer 
management; the common theme being that surgery is the gold-standard treatment.  
Surgery is not benign and without its own morbidities.  Surgical patients are anxious 
about the surgery itself, the risks associated with the procedure, post-operative healing 
concerns, and the prospect of a disfiguring scar (Brandt et al., 2012; Yeung et al., 2014).   
Given these morbidities a societal shift has focused on skin cancer risk minimization – 
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i.e., avoiding high UV periods, covering up exposed skin, and using sunscreen.  In spite 
of these minimization strategies, over 3 million cases of non-melanoma skin cancer 
present annually worldwide (Vogel, 2018).  Thus, a concerted effort continues to focus 
on minimizing treatment related morbidity through well-camouflaged reconstructive 
surgery and scar minimization.   
Facial Scarring 
 The negative psychological impact of an acquired facial scar has been well 
documented (Borah & Rankin, 2010; Brown et al., 2008; Ishii et al., 2009; Kim et al., 
2013; Levine et al., 2005; Rankin & Borah, 2003; Sobanko et al., 2015; Tebble et al., 
2006; Van Den Elzen et al., 2012).   Predictably an entire industry has been built around 
the aesthetic improvement of scars with limited empiric evidence to support commercial 
promises (Brandt et al., 2009).  Similar to commerce and in-part to minimize scarring, 
many surgical interventions have shifted focus to becoming “minimal access”, “key-
hole”, or “incisionless”.  Thus, the focus on scar minimization has been paramount in 
both medical and para-medical cultures.   Surprisingly and in spite of this focus, there has 
been no empirically established gold-standard tool for evaluating scars.   
Scar Scaling 
As highlighted in Chapter 4, contemporary scar scales suffer from conflicts in the 
dimensions that are scaled, inconsistencies in how these dimensions are scaled, and are 
inherently flawed relative to the mathematical assumptions underlying their scaling 
techniques (Brandt et al., 2009).  The proposed Scar Camouflage Scale and the rigor by 
which its preliminary validity testing was established strives to overcome these 
challenges.  Key dimensions for scar evaluation were identified and refined through this 
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preliminary validity testing and are summarized in Table 5.1.  One of the findings from 
our preliminary validity testing was that the dimension “Irregularity” was more variably 
scaled and based on this finding, “Texture” is proposed as an improved hinge word for 
this dimension. Future investigations will need to compare this to the original 
“Irregularity” data set.  Further, the dimension of “Impact” was proposed as a means of 
capturing the effect of the scar on the individual’s overall appearance – a unique 
dimension that to our knowledge, has not previously been captured in the scar evaluation 
literature.    
 
Table 5.1:  Scar Evaluation Dimensions 
 
Dimensions 
Width 
Height 
Pliability 
Discoloration 
Texture 
Distortion* 
Evidence of Surgery 
Camouflage 
Impact** 
Note. *Texture replaces “Irregularity” and **Impact is a newly proposed dimension. 
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Thus, based on the work highlighted in Chapter 4, empiric evidence has been 
established to support the development of the Scar Camouflage Scale as an effective and 
reliable means of scar evaluation.  Nevertheless, more work must be done to refine this 
scale to ensure real-world applicability.   
Clinical Implications 
 While some components of empiric scar scaling appeals to academic curiosity, the 
ability to accurately and objectively evaluate a scar forms the foundation for real clinical 
work.  This is so fundamental, that at present health care providers do not even have an 
accurate way of documenting or discussing a scar beyond “it’s good” or “it’s bad”.  
Providing an objective and reliable method for documenting scar severity sets the stage 
for real-world applicability.  
 Armed with a reliable scar scale we can begin to understand and appreciate the 
factors – both positive and negative – that determine individual scar acceptability.  This 
knowledge provides the basis for comprehensive pre-operative counselling.   Factors 
identified as “protective” against negative scar acceptability can potentially be fostered to 
improve an individual’s capacity for scar acceptance.  Alternatively, the identification of 
“hindering” factors can allow for early counselling and intervention.  This step provides 
the means of moving beyond the scar itself and allowing the integration of the 
psychosocial factors that contribute to an individual’s overall well-being and social 
participation.   
 While wholistic patient care is the goal of any medical intervention, a reliable scar 
scale also provides the basis for improving scars themselves.    A “good” post-operative 
scar is an outcome believed to result from favorable patient wound-healing biology, 
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meticulous surgical technique, and conscientious wound aftercare.  Curiously, surgical 
technique and wound aftercare are non-standardized and largely the dogma of 
apprenticeship surgical training.  It is not uncommon to hear surgical trainees ask their 
expert mentor’s why a particular technique is used and be told “this is how we’ve done it 
for decades”.  Anecdotal experience has been the longstanding basis of surgical training.   
The Scar Camouflage Scale provides an instrument by which surgical wound closure 
technique and aftercare can be empirically investigated.  Does a particular angle of 
incision, suturing technique, type of suture, or aftercare strategy result in superior scars?  
Why is it that some surgeons can achieve better scars than others? The answers to these 
questions have the potential to fundamentally change the way surgical wounds are closed 
and cared for worldwide.  
Directions for Future Research 
 Standardized scar evaluation is the bottleneck to holistically understanding skin 
scarring as a health condition.  As discussed in Chapter 3, any attempt to apply the ICF 
framework or more simply to evaluate the psychosocial consequences of a facial scar 
relies on the ability to accurately characterize a scar.  We implicitly understand that a 
more self-conscious individual will be more psychosocially affected by a scar, but how 
self-conscious do they need to be, what is the smallest scar that contributes to this 
outcome, and how does this consequence translate to their social or vocational 
functioning?  The Scar Camouflage Scale provides the necessary basis for addressing 
these questions as it provides the fundamental objective quantification of the scar itself.  
The scaled scar measurement can then be hinged to multiple demographic features 
including age, gender, socioeconomic status, etc., and subsequently compared to 
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validated quality of life metrics and patient reported outcome measures to provide truly 
meaningful insight on the scar specific factors that most contribute to positive or negative 
psychosocial outcomes.   
 The preliminary testing of the Scar Camouflage Scale included the development 
of the SCaRS Rating Software.  This provided a time-efficient means of acquiring scar 
rating data.  While a research tool used in a lab is fundamental to scar characterization 
research, prospectively modifying the software to create a scar rating handheld device 
application (i.e., iOS, Google, etc.) could provide a means of acquiring massive amounts 
of data from a robust worldwide population.  This app could potentially allow for the 
largest possible scar evaluation study – providing an entirely new way of acquiring scar 
evaluation data.   
 As hinted at previously, how an individual views their own scar is vital to their 
acceptance of the scar and the effects of that scar on their social and vocational 
functioning (Tebble et al., 2006).   The “impact” of the scar on their perceived 
appearance and the subsequent ramifications are a critical area for future research.  
Further, identifying the relationship between objective and subjective “impact” is critical 
to pre-operative patient counselling.   To this end, further validity testing is necessary to 
determine how well the Scar Camouflage Scale captures an individual’s subjective self-
rating of their own scar.  Once established, self-ratings of scars can then be compared to 
objective evaluations of the same scar by neutral observers.  These results alongside 
individual demographics and well validated self-consciousness and anxiety outcome 
measures such as the Derriford Appearance Scale (Harris & Carr, 2001) will yield critical 
information that will change how we understand facial scarring.     
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Limitations of the Present Project 
 The goal of this body of work was to highlight our understanding of facial 
scarring and provide a means of improving upon current scar evaluation scales.  Like all 
research it is not without its limitations.   
 To allow for scientific rigor and standardization, the photographs of the scars 
presented to the participants of the reliability testing of Chapter 4 were exclusively photos 
of linear (i.e., straight line) scars of varying severity.  As we know, scars come in a 
variety of shapes and sizes which can include wide burn scars, narrow surgical scars, or 
flat skin graft donor site scars.  Thus, the utility of the Scar Camouflage Scale will need 
to be determined amongst a more broad range of scars.   
 The participants who served as scar observers and scar raters in our Scar 
Camouflage Scale reliability testing were derived from a population of volunteer 
university students, university employees, and hospital workers from Southwestern 
Ontario.  While the age range of participants was quite broad (19 to 63 years), most of 
these participants were women (25 out of 34).  It is expected, that perceived scar severity 
varies across many factors which may include socioeconomic status, gender, culture, 
race, religion, and country.  Thus, while our reliability testing demonstrated stable results 
even amongst a small pool of participants, result stability may vary when applied to a 
larger more diverse population.  Further work must thus be done to validate the scar 
camouflage scale.  
  Similar to the aforementioned concerns relative to a particular sample size, the 
utility of the Scar Camouflage Scale has not been determined amongst individuals with 
scars themselves or professional scar observers.  Conceivably acquiring a scar impacts 
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how one perceives scar severity. Professional observers – i.e., those who regularly care 
for scars as part of their vocation (i.e., nurse, surgeon, etc.) – may view scars differently 
than non-professional observers.  Perhaps surgically creating scars, visualizing the 
outcome of this work, or professionally caring for scars may alter one’s internal gauge for 
determining scar outcomes.  To this end, further validity testing is necessary within these 
population groups and between these population groups as the results define the true 
applicability of the Scar Camouflage Scale.  
 Finally, this work is current as of its writing and is likely not the only 
investigation focusing on scar evaluation.  While every effort was made to integrate the 
latest investigations on scar outcomes, given the velocity of scientific research, it is 
possible that a novel and very reliable scar scale could be in the process of validity testing 
that is superior to the current work.  While this possibility exists, the numerous directions 
for future research remain important goals that can be achieved irrespective of the 
specific measurement tool applied – albeit the tool must be rigorously validated.   
 Summary 
In summary, facial skin scarring is a substantial problem with a real and tangible 
impact on an individual’s self-perceived attractiveness, self-esteem, social acceptance, 
and overall societal and vocational functioning.  This body of research has reviewed the 
challenges associated with facial skin scars, the most common mechanism by which 
facial scars are obtained (i.e., skin cancer) and the need for more holistic approaches to 
scar characterization and measurement.    
The robust development of a novel scar evaluation scale was proposed.  It is 
encouraging that our preliminary validity testing provides a springboard for future 
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research.  Findings of this research have the potential to help understand the factors that 
impact skin scar development and thereby direct caregivers in their efforts towards scar 
minimization.  At the same time, future research can be directed to the factors that impact 
upon subjective and objective scar characterization and acceptability, ideally with the 
goal of improving direct patient counselling both pre- and post-scar development.   
In seeking to establish a novel scar evaluation scale, the unique SCaRS Rating 
Software was developed.  This tool provides a robust, adaptable, and time-efficient means 
for acquiring enormous amounts of scar rating data (i.e., nine-dimension measurements 
for each scar photo for every scar observer).   Thus, we now have the scar rating tool, the 
timesaving software, and a means of data acquisition to propel clinical scar research 
forward.   
In conclusion, this work has provided the background and direction for a robust 
program of research into the evolution and impact of scars.  Consequently, the outcome 
of this research has the potential to impact on every individual who acquires a scar 
through any means.  While scars may be inevitable, we now have the background and 
tools available to minimize the scars of the future and the impact on those we serve.   
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of Otolaryngology – Head and Neck Surgery.    Montreal, Quebec, Canada. May 2017. 
 
Managing Moles & Cysts of the Head and Neck. 
Brandt MG.  
Lumps, Bumps & Looks in the Head and Neck Course.  Division of Facial Plastic & 
Reconstructive Surgery. Department of Otolaryngology – Head and Neck Surgery, Faculty 
of Medicine, University of Toronto    Toronto, Ontario, Canada. April 2017. 
 
Facial trauma for the Otolaryngologist – Head & Neck Surgeon.  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2017. 
 
Rhinoplasty: the basics for the Royal College examination.  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2017. 
 
Preparing for the Royal College oral examination in facial plastic & reconstructive 
surgery.  
Brandt MG. 
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2017. 
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Facial analysis for Rhinoplasty  
Brandt MG.  
Annual Clinic Day of the Canadian Academy of Facial Plastic and Reconstructive Surgery.  
Toronto, Ontario, Canada. October 2016. 
 
Planning for Skin Cancer Excisions 
Brandt MG. 
Caring for Skin Cancer and the Aging Face in Family Practice. Division of Facial Plastic & 
Reconstructive Surgery. Department of Otolaryngology – Head and Neck Surgery, Faculty 
of Medicine, University of Toronto    Toronto, Ontario, Canada. June 2016. 
 
Scar Revision 
Brandt MG. 
2016 Annual McGill Facial Plastic & Reconstructive Surgery Course.  McGill Department 
of Otolaryngology – Head and Neck Surgery.    Monreal, Quebec, Canada. May 2016. 
 
Functional Rhinoplasty: evidence based management of poor nasal breathing 
Brandt MG. 
2016 Septorhinoplasty Update.  University of Toronto Department of Otolaryngology – 
Head and Neck Surgery.    Toronto, Ontario, Canada. February 2016. 
 
Facial trauma for the Otolaryngologist – Head & Neck Surgeon.  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2016. 
 
Rhinoplasty: the basics for the Royal College examination.  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2016. 
 
Preparing for the Royal College oral examination in facial plastic & reconstructive 
surgery.  
Brandt MG. 
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2016. 
 
Otolaryngology – Head and Neck Surgery Unemployment: a cross-sectional survey of 
graduating Otolaryngology – Head and Neck Surgery residents. 
Brandt MG.  
Annual Meeting of the Canadian Society of Otolaryngology – Head & Neck Surgery, 
Winnipeg, Manitoba, Canada.  June 2015.  
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Cases in Facial Reconstruction 
Brandt MG. 
2015 Annual McGill Facial Plastic & Reconstructive Surgery Course.  McGill Department 
of Otolaryngology – Head and Neck Surgery.    Montreal, Quebec, Canada. May 2015. 
 
Facial trauma for the Otolaryngologist – Head & Neck Surgeon.  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2015. 
 
Rhinoplasty: the basics for the Royal College examination  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2015. 
 
Preparing for the Royal College oral examination in facial plastic & reconstructive 
surgery.  
Brandt MG. 
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2015. 
 
Otolaryngology – Head and Neck Surgery Unemployment: a cross-sectional survey of 
graduating Otolaryngology – Head and Neck Surgery residents. 
Brandt MG.  
Annual Royal College – National Specialty Societies Human Resources for Health 
Dialogue.  Royal College of Physicians and Surgeons of Canada, Ottawa, Ontario, Canada.  
December 2014.  
 
Local flaps in nasal reconstruction 
Brandt MG.  
Grand Rounds Presentation.  Department of Surgery, Southlake Regional Health Centre, 
Newmarket, Ontario, Canada.  November 2014.  
 
Facial analysis  
Brandt MG.  
Annual Clinic Day of the Canadian Academy of Facial Plastic and Reconstructive Surgery.  
Toronto, Ontario, Canada. October 2014. 
 
Facial trauma for the Otolaryngologist – Head & Neck Surgeon.  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2014. 
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Rhinoplasty: the basics for the Royal College examination  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2014. 
 
Preparing for the Royal College oral examination in facial plastic & reconstructive 
surgery.  
Brandt MG. 
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2014. 
 
An evidence based approach to nasal fractures.  
Brandt MG. 
Annual Clinic Day of the Canadian Academy of Facial Plastic and Reconstructive Surgery.  
Toronto, Ontario, Canada. October 2013. 
 
Facial analysis  
Brandt MG.  
Visiting Lecturer Teaching Rounds.  Division of Otolaryngology – Head and Neck 
Surgery, Department of Surgery, McMaster University. Hamilton, Ontario, Canada.  
October 2013.  
 
Facial trauma for the Otolaryngologist – Head & Neck Surgeon.  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2013. 
 
Rhinoplasty: the basics for the Royal College examination  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2013. 
 
Preparing for the Royal College oral examination in facial plastic & reconstructive 
surgery.  
Brandt MG. 
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2013. 
 
Nasal anatomy and analysis for rhinoplasty 
Brandt MG.  
Annual Clinic Day of the Canadian Academy of Facial Plastic and Reconstructive Surgery.  
Toronto, Ontario, Canada.  October 2012.  
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Local flaps in nasal reconstruction 
Brandt MG.  
Visiting Lecturer Teaching Rounds.  Division of Otolaryngology – Head and Neck 
Surgery, Department of Surgery, McMaster University. Hamilton, Ontario, Canada.  
September 2012.  
 
Rhinoplasty: patient selection, anatomy, & analysis. 
Brandt MG. 
Canadian Society of Otolaryngology – Head and Neck Surgery / University of Toronto 
Department of Otolaryngology – Head and Neck Surgery Rhinoplasty Course. Toronto, 
Ontario, Canada. May 2012. 
 
What is a Facial Plastic & Reconstructive Surgeon? 
Brandt MG.  
Visiting Lecturer Rounds.  Department of Family Medicine, Queens University.  Kingston, 
Ontario, Canada.  February 2012. 
 
Facial trauma for the Otolaryngologist – Head & Neck Surgeon.  
Brandt MG.  
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2012. 
 
Preparing for the Royal College oral examination in facial plastic & reconstructive 
surgery.  
Brandt MG. 
Annual Otolaryngology – Head & Neck Surgery Review Course.  Halifax, Nova Scotia, 
Canada.  January 2012. 
 
The history of facial plastic & reconstructive surgery in Canada.   
Brandt MG, Moore CC, Conrad K. 
Annual Clinic Day of the Canadian Academy of Facial Plastic and Reconstructive Surgery.  
Toronto, Ontario, Canada.  October 2009. 
 
 
Peer-reviewed podium presentations: 
 
The aesthetic unit principle. 
Brandt MG, Tan S, Doyle PC, Moore CC 
Annual Meeting of the American Academy of Facial Plastic & Reconstructive Surgery.  
New Orleans, LA, United States of America. October 2013.   
 
Preliminary validation of a novel scale for the objective evaluation of linear scars. 
Brandt MG, Moore CC, Parsa V, Moyer JS, Baker SR, Doyle PC. 
Annual Meeting of the American Academy of Facial Plastic & Reconstructive Surgery.  
Washington, DC, United States of America. September 2012.   
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Preliminary validation of a novel scale for the objective evaluation of linear scars. 
Brandt MG, Moore CC, Parsa V, Moyer JS, Baker SR, Doyle PC.   
International Federation of Facial Plastic Surgery Societies (IFFPSS) VII International 
Congress.  Rome, Italy.  May 2012. 
 
Developing a novel scale for the objective evaluation of linear scars. 
Brandt MG, Moore CC, Parsa V, Doyle PC.   
Annual Meeting of the Canadian Society of Otolaryngology – Head and Neck Surgery. 
Victoria, British Columbia, Canada.  May 2011. 
 
The history of facial plastic & reconstructive surgery in Canada.  
Brandt MG, Moore CC, Conrad K. 
Annual Meeting of the Canadian Society of Otolaryngology – Head and Neck Surgery. 
Niagara Falls, Ontario, Canada.  May 2010. 
 
A prospective evaluation of perioperative concern amongst patients considering 
thyroidectomy.   
Brandt MG, Franklin JH, Osborn HA, Fung K, Yoo J, Doyle PC. 
World Congress on Thyroid Cancer. Toronto, Ontario, Canada.  August 2009. 
 
A prospective evaluation of perioperative concern amongst patients considering 
thyroidectomy.   
Brandt MG, Franklin JH, Osborn HA, Fung K, Yoo J, Doyle PC. 
Annual Meeting of the Canadian Society of Otolaryngology – Head and Neck Surgery. 
Halifax, Nova Scotia, Canada.  May 2009. 
 
Atrophy amongst mucosa only versus muscular mucosa superiorly based pharyngeal 
flaps.  
Brandt MG, Husein M, Matic D, Leung A, Wehrli B, Welch I, Doyle PC.   
Junior Investigator Competition, Annual American Cleft Palate – Craniofacial Association 
Meeting. Scottsdale, Arizona, United States of America. April 2009. 
 
A prospective randomized evaluation of scar assessment measures.  
Brandt MG, Moore CC, Micomonaco D, Fung K, Franklin JH, Yoo J, Doyle PC. 
Annual Eastern Section Triologic Society Meeting.  Boston, Massachusetts, United States 
of America. January 2009. 
 
A needs assessment of undergraduate education in Otolaryngology amongst Family 
Medicine residents.   
Glicksman JT, Brandt MG, Parr J, Fung K.   
Annual Meeting of the Canadian Society of Otolaryngology – Head and Neck Surgery. 
Jasper, Alberta, Canada.  May 2008. 
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Clinical evaluation of a novel internal nasal dilation stent for the improvement of 
nasal breathing.  
Brandt MG, Moore CC, Doyle PC.   
Annual Eastern Section Triologic Society Meeting.  Philadelphia, Pennsylvania, United 
States of America. January 2008. 
 
A randomized control trial of fluorescence guided surgical excision of nonmelanotic 
cutaneous malignancies.   
Brandt MG, Moore CC, Jordan K. 
Poliquin Medtronic-Xomed Resident Research Competition – Annual Meeting of the 
Canadian Society of Otolaryngology – Head and Neck Surgery.  Kelowna, British 
Columbia, Canada. May 2006. 
 
Visual spatial ability, learning modality and surgical knot tying.   
Brandt MG, Davies ET. 
Annual Meeting of the Royal College of Physicians and Surgeons of Canada.  Ottawa, 
Ontario, Canada. October 2004. 
 
Medical student career choice and mental rotations ability.   
Brandt MG, Wright ED. 
Annual Meeting of the Royal College of Physicians and Surgeons of Canada.  Ottawa, 
Ontario, Canada.  October 2004. 
 
Symptoms, acid exposure, and motility in patients with Barrett’s esophagus.   
Brandt MG, Darling GE, Miller L. 
Annual Meeting of the Canadian Association of Thoracic Surgeons.  London, Ontario, 
Canada.  September 2002. 
 
 
Peer-Reviewed Posters: 
 
Oyewumi M, Brandt MG, Carrillo B, Atkinson A, Iglar K, Forte V, Campisi P.  Objective 
evaluation of otoscopy skills among family and community medicine, pediatric, and 
Otolaryngology Residents. Annual Meeting of the Canadian Society of Otolaryngology – 
Head and Neck Surgery.  Charlottetown, Prince Edward Island, Canada.   
 
Roach V, Brandt MG, Moore CC, Wilson TD.   The evaluation of 3D videography as a 
surgical training tool.  2011 University of Western Ontario Annual Anatomy and Cell 
Biology Research Day.  London, Ontario, Canada. 
 
Abdul-Sater L, Henry M, Mjovic T, Brandt MG, Franklin JH, Black MJ, Hier MP, Payne 
RJ.  What are thyroidectomy patients really concerned about? A prospective evaluation of 
perioperative concerns amongst patients considering thyroidectomy.  2010 Annual meeting 
of the American Academy of Otolaryngology.  Boston, Massachusetts, USA.  
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Brandt MG, Moore CC, Micomonaco D, Fung K, Franklin JH, Yoo J, Doyle PC. Clinical 
evaluation of scars: are we measuring correctly? 2008 Annual meeting of the American 
Academy of Facial Plastic and Reconstructive Surgery. Chicago, Illinois, USA. 
 
Brandt MG, Wright ED.  Chronic maxillary atelectasis is the silent sinus syndrome.  2007 
Combined Otolaryngology Spring Meeting. San Diego, California, USA. 
 
 
Chaired courses & workshops: 
 
2019 Complications, Pearls & Pitfalls in Facial Reconstruction 
Panel Discussion Chair 
Co-Presenters: Moore CC, Taylor SM, Ansari K. 
Annual Meeting of the Canadian Society of Otolaryngology – Head & 
Neck Surgery. Edmonton, Alberta, June 2019 
  
2019 Case-Based Panel Discussion: Interesting Cases  
Panel Discussion Chair 
Co-Panelists: Witterick I, Davids T, Lin J 
OTOUpdate 2019  
Toronto, Ontario, February 2019 
  
2018 Facial Plastic & Reconstructive Surgery Paper Presentations 
Paper Presentation Chair 
Annual Meeting of the Canadian Society of Otolaryngology – Head & 
Neck Surgery. Quebec City, Quebec, June 2018. 
  
2018 Lumps, Bumps & Looks in the Head and Neck. 
Course Director  
Accredited 3.5hr CME event covering a broad spectrum of topics in 
skin cancer, oral pathology, occuloplastic lesions, facial reconstruction, 
and facial aesthetics.  Toronto, Ontario, April, 2018 
  
2017 Nasal reconstruction: a specialist panel on the contemporary 
reconstruction of the face. 
Co-Presenters: Moore CC, Taylor SM, Ansari K, Hekkenberg R. 
Annual Clinical Day of the Canadian Academy of Facial Plastic & 
Reconstructive Surgery. Toronto, Ontario, October 2017. 
  
2017 Complications, Pearls & Pitfalls in Facial Reconstruction 
Co-Presenters: Moore CC, Taylor SM, Trites J 
Annual Meeting of the Canadian Society of Otolaryngology – Head & 
Neck Surgery. Saskatoon, Saskatchewan, June 2017. 
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2017 Facial Plastic & Reconstructive Surgery Paper Presentations 
Paper Presentation Chair 
Annual Meeting of the Canadian Society of Otolaryngology – Head & 
Neck Surgery. Saskatoon, Saskatchewan, June 2017. 
  
2017 Nasal reconstruction: a specialist panel on the contemporary 
reconstruction of the face. 
Co-Presenters: Moore CC, Taylor SM, Trites J 
Annual Meeting of the Canadian Society of Otolaryngology – Head & 
Neck Surgery. Saskatoon, Saskatchewan, June 2017. 
  
2016 Lumps, Bumps & Looks in the Head and Neck: An update in 
Dermatology and Facial Plastic & Reconstructive Surgery. 
Course Director  
Accredited 3.5hr CME event covering a broad spectrum of topics in 
skin cancer, facial reconstruction, and facial aesthetics.  Toronto, 
Ontario, April, 2017 
  
2016 Nasal reconstruction: a specialist panel on the contemporary 
reconstruction of the face. 
Co-Presenters: Moore CC, Taylor SM, Ansari K, Trites J, Bonaparte J. 
Annual Clinical Day of the Canadian Academy of Facial Plastic & 
Reconstructive Surgery. Toronto, Ontario, October 2016. 
  
2016 Facial reconstruction: a specialist panel on the contemporary 
reconstruction of the face. 
Co-Presenters: Tasman A, Taylor SM, Ansari K, Trites J, Moore CC. 
Annual Meeting of the Canadian Society of Otolaryngology – Head & 
Neck Surgery. Charlottetown, Prince Edward Island, June 2016.  
  
2016 Caring for skin cancer and facial aesthetics in family practice: An 
update in Dermatology and Facial Plastic & Reconstructive 
Surgery. 
Course Director  
Accredited 6.5hr CME event covering a broad spectrum of topics in 
skin cancer, facial reconstruction, and facial aesthetics.  Toronto, 
Ontario, June 2016 
  
2015 Facial reconstruction: a specialist panel on the contemporary 
reconstruction of the face. 
Co-Presenters: Moore CC, Taylor SM, Ansari K, Trites J. 
Annual Clinical Day of the Canadian Academy of Facial Plastic & 
Reconstructive Surgery. Toronto, Ontario, October 2015. 
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2015 Facial reconstruction: a specialist panel on the contemporary 
reconstruction of the face. 
Co-Presenters: Sykes J, Taylor SM, Ansari K, Trites J. 
Annual Meeting of the Canadian Society of Otolaryngology – Head & 
Neck Surgery. Winnipeg, Manitoba, June 2015.  
  
2015 An evidence based approach to nasal trauma. 
Co-Presenter: Taylor SM. 
Annual Meeting of the Canadian Society of Otolaryngology – Head & 
Neck Surgery. Winnipeg, Manitoba, June 2015. 
  
2014 Facial reconstruction: a specialist panel on the contemporary 
reconstruction of the face. 
Co-Presenters: Taylor SM, Ansari K, Moore CC, Trites J. 
Annual Clinical Day of the Canadian Academy of Facial Plastic & 
Reconstructive Surgery. Toronto, Ontario, October 2014.  
  
2012 Facial reconstruction: a specialist panel on the contemporary 
reconstruction of the face. 
Co-Presenters: Higgins K, Ansari K, Taylor SM, Moore CC. 
Annual Meeting of the Canadian Society of Otolaryngology – Head 
and Neck Surgery. Toronto, Ontario, May 2012.  
  
2012 A comprehensive review and update in facial plastic surgery. 
Co-Presenters: Taylor SM, Ellis DAF, Moore CC 
Annual Meeting of the Canadian Society of Otolaryngology – Head 
and Neck Surgery. Toronto, Ontario, May 2012.  
  
2011 US fellowships: options, immigration and application explained. 
Co-Presenters: Raza SN, Annand S. 
Annual Meeting of the Canadian Society of Otolaryngology – Head 
and Neck Surgery. Victoria, British Columbia, May 2011.  
  
2011 Local flap reconstruction for the Otolaryngologist – Head and 
Neck Surgeon. 
Annual Meeting of the Canadian Society of Otolaryngology – Head 
and Neck Surgery. Victoria, British Columbia, May 2011.  
  
2011 Upper & lower facial trauma for the Otolaryngologist – Head and 
Neck Surgeon. 
Annual Meeting of the Canadian Society of Otolaryngology – Head 
and Neck Surgery. Victoria, British Columbia, May 2011.  
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2010 Facial trauma for the Otolaryngologist – Head and Neck Surgeon. 
Co-Presenter: Moore CC. 
Annual Meeting of the Canadian Society of Otolaryngology – Head 
and Neck Surgery. Niagara Falls, Ontario, Canada.  May 2010. 
 
 
Academic achievements & awards: 
 
2010 2010 Thomas Martin Golden Throat Award 
Annual award for the most outstanding scientific presentation amongst 
Otolaryngology residents at the University of Western Ontario. 
  
2010 2010 Undergraduate Otolaryngology Teaching Award 
Annual award presented by undergraduate medical students to an 
Otolaryngology resident for outstanding teaching during their third 
year clinical clerkship. 
  
2009 2009 Outstanding Surgical Teaching Award 
Quarterly award for the most outstanding surgical resident educator for 
medical students completing their clinical clerkship.   
  
2009 2009 C.A. Thompson Award for Scientific Achievement in 
Otolaryngology 
Annual award for the most outstanding research project amongst 
Otolaryngology residents at the University of Western Ontario.  
  
2008 2008 University Students’ Council Teaching Honour Roll: Award 
of Excellence – Medicine 
Annual university-wide teaching award based upon undergraduate 
medical student nominations of a lecturer at the University of Western 
Ontario. 
  
2008 2008 C.A. Thompson Award for Scientific Achievement in 
Otolaryngology 
Annual award for the most outstanding research project amongst 
Otolaryngology residents at the University of Western Ontario.  
  
2008 2008 Undergraduate Otolaryngology Teaching Award 
Annual award presented by undergraduate medical students to an 
Otolaryngology resident for outstanding teaching during their third 
year clinical clerkship. 
  
2007 2007 Thomas Martin Golden Throat Award 
Annual award for the most outstanding scientific presentation amongst 
Otolaryngology residents at the University of Western Ontario. 
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2007 2007 Undergraduate Otolaryngology Teaching Award 
Annual award presented by undergraduate medical students at the 
University of Western Ontario to an Otolaryngology resident for 
outstanding teaching during their third year clinical clerkship. 
  
2006 2006 Paediatric Surgery Resident Research Award (Division of 
Paediatric Surgery Research Competition) 
One of two awards for excellence in Paediatric research amongst 
postgraduate trainees at the University of Western Ontario. 
  
2001 Fourth Year Undergraduate Psychology Prize 
Awarded to the undergraduate student with the highest GPA amongst 
graduating B.Sc. (Specialized Honours) Psychology students at York 
University 
 
2001 Bethune College Masters Prize 
An annual award to the undergraduate student who has most 
contributed to Bethune College (York University) 
  
2000, 2001 Bethune College Masters Honour Roll 
An annual award to undergraduate students who have made significant 
contributions to Bethune College (York University) 
  
1998 – 2001 Deans Honour Roll 
York University 
  
1999 Undergraduate Academic Scholarship 
York University 
  
1998 Merit Award 
York University 
 
 
Professional extracurricular activities: 
 
2019 – Present Scientific Co-Chair 
Section of Facial Plastic & Reconstructive Surgery  
International Federation of Otolaryngology Societies 2021 Vancouver 
Meeting 
  
2018 – Present Reviewer & Podium Presentation Chair 
Facial Plastic & Reconstructive Surgery Podium Presentation & Poster 
Submissions 
Canadian Society of Otolaryngology Annual Meeting 
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2017 – Present Section of Otolaryngology - Delegate 
Ontario Medical Association 
 
2016 – Present Ontario Regional Representative 
Canadian Academy of Facial Plastic & Reconstructive Surgery 
 
2014 – Present Co-director; Resident Soft-Tissue Dissection Course 
Division of Facial Plastic & Reconstructive Surgery 
Department of Otolaryngology – Head and Neck Surgery 
Faculty of Medicine, University of Toronto 
  
2014 – Present Ontario Regional Representative  
Canadian Society of Otolaryngology – Head and Neck Surgery 
 
2011 – 2017 Fellowship Committee 
American Academy of Facial Plastic and Reconstructive Surgery 
 
2010 – 2017 Membership & Residency Relations Committee 
American Academy of Facial Plastic and Reconstructive Surgery 
  
2010 – 2017 Research Committee 
American Academy of Facial Plastic and Reconstructive Surgery 
  
2015– 2016 Grant Reviewer 
Combined Otolaryngology Research Effort (CORE) Grant Review 
American Academy of Otolaryngology – Head and Neck Surgery 
  
2010 – 2016 Young Physicians Committee 
American Academy of Facial Plastic and Reconstructive Surgery 
  
2014 – 2015 Grant Reviewer 
Combined Otolaryngology Research Effort (CORE) Grant Review 
American Academy of Otolaryngology – Head and Neck Surgery 
American Academy of Facial Plastic & Reconstructive Surgery 
  
2012 – 2016 Electronic Communication Chair 
Canadian Society of Otolaryngology – Head and Neck Surgery 
 
2004 – 2011 Interviewer  
Schulich School of Medicine Admissions Committee 
University of Western Ontario 
  
2008 - 2009 Resident Representative, Postgraduate Education Committee 
Department of Otolaryngology, University of Western Ontario 
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2007 – 2009 Resident Representative, University of Western Ontario 
American Academy of Otolaryngology – Head and Neck Surgery 
  
2007 Resident Representative, Undergraduate Education Committee 
Department of Otolaryngology, University of Western Ontario 
 
 
Volunteerism: 
 
2015 Toronto Indy, Toronto, Ontario, Canada 
Ontario Race Physicians - Volunteer Otolaryngology – Head and Neck 
Surgeon to the drivers and race teams at the 2015 Toronto Indy. 10hrs. 
  
2015 Pan & Parapan American Games, Toronto, Ontario, Canada 
Volunteer Otolaryngology – Head and Neck Surgeon to the athletes 
and international delegates to the 2015 Pan Am and Para Pan Am 
Games. 25 hrs. 
  
2011 University of Michigan Hope Clinic 
Combined University of Michigan Departments of Otolaryngology & 
Plastic Surgery charitable clinic for uninsured patients in the Michigan 
area. 
  
2009 Medical Mission to La Ceiba, Honduras 
University of Michigan medical mission.  Provided clinical and 
operative care to children and adults affected by conditions of the head 
and neck. 
 
 
Journal reviewer: 
 
2019 – Present Canadian Medical Association Journal  
  
2017 – Present Journal of Surgical Education 
  
2012 – Present Anatomical Sciences Education 
  
2011 – Present International Forum of Allergy & Rhinology 
  
2010 – Present American Journal of Rhinology & Allergy 
  
2008 – Present The Laryngoscope 
  
2007 – Present Journal of Otolaryngology – Head and Neck Surgery 
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Professional memberships: 
 
Canadian Society of Otolaryngology – Head and Neck Surgery (CSOHNS) 
 
American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) 
 
Canadian Academy of Facial Plastic and Reconstructive Surgery (CAFPRS) 
 
European Academy of Facial Plastic Surgery (EAFPS) 
 
Royal College of Physicians and Surgeons of Canada 
 
Canadian Medical Association (CMA) 
 
Ontario Medical Association (OMA) 
 
 
Licensure & certification: 
 
2019 Advanced Cardiac Life Support (ACLS®) Provider 
Basic Life Support (BLS®) Provider 
  
2011 College of Physicians and Surgeons of Nova Scotia 
Independent Medical Practice License: 18085 
  
2018 American Board of Facial Plastic & Reconstructive Surgery  
Certification in Facial Plastic & Reconstructive Surgery / Diplomate 
ABFPRS 
  
2011 American Board of Facial Plastic & Reconstructive Surgery  
Comprehensive Examination in Facial Plastic & Reconstructive 
Surgery 
  
2011 College of Physicians and Surgeons of Ontario 
Independent Medical Practice License: 82477 
  
2010 Advanced Cardiac Life Support (ACLS®) Provider 
  
2010 Royal College of Physicians and Surgeons of Canada 
Fellowship Examination in Otolaryngology – Head and Neck Surgery 
(FRCSC) 
Membership: 673990 
  
2010 United States of America Drug Enforcement Agency (DEA) Narcotic 
License 
License: FB2085389 
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2010 State of Michigan 
Independent Medical Practice License: 4301095791 
  
2009 United States Medical Licensing Examination (USMLE) 
Step III 
  
2008 United States Medical Licensing Examination (USMLE) 
Step II (CS & CK) 
  
2007 United States Medical Licensing Examination (USMLE) 
Step I 
  
2007 Advanced Trauma Life Support (ATLS®) Instructor 
  
2007 Royal College of Physicians and Surgeons of Canada 
Principles of Surgery (POS) Examination 
  
2006 Medical Council of Canada (MCC) 
Physician Qualifying Examination Part II 
 Licentiate Number: 101164 
  
2005 College of Physicians and Surgeons of Ontario 
Education Practice License: 82477 
  
2005 Medical Council of Canada (MCC) 
Physician Qualifying Examination Part I 
  
2005 Laser Fundamentals & Safety Certification 
  
2005 Advanced Trauma Life Support (ATLS®) Provider 
  
2005 Advanced Cardiac Life Support (ACLS®) Provider 
 
 
Non-academic achievements & awards: 
 
1997 10th Place, Karate, 15th World Maccabiah Games 
Tel Aviv, Israel 
  
1996 Black Belt – 1st Dan – Taekwondo 
International Taekwondo Federation 
  
1996 Black Stripe – 1st Kyu – Ninjutsu/Ninpo 
Genbukan Ninpo Bugei 
 
